주메뉴
- 나의 진료정보
- 진료안내
-
병원소개
찾아오시는길
분당서울대학교병원에 찾아오시는 길입니다.
우)13620, 경기도 성남시 분당구 구미로173번길 82
대중교통 이용-
- 미금역에서 버스 이용시
- 미금역 3번 출구 → 마을버스(7번, 7-1번), 8446번 버스 탑승 → 분당서울대학교병원
- 미금역 2번 출구 → 51번 버스 탑승 → 분당서울대학교병원
- 미금역 8번 출구 → 마을버스(19번), 380번 버스 탑승 → 분당서울대학교병원
-
- 오리역에서 버스 이용시
- 오리역 7번 출구 → 10m 앞 마을버스(19번) 탑승 → 분당서울대학교병원
-
- 정자역에서 버스 이용시
- 정자역 3번 출구 → 마을버스(19번, 111번), 380번, 8446번 버스 탑승 → 분당서울대학교병원
-
- 헬스케어혁신파크(상행) 하차시
- 분당서울대학교병원 방향 탄천길로 도보 15분
자동차 이용-
- 판교 IC 방면
- 판교 IC → 분당방향으로 직진 → 서현로 → 분당구청 방향으로 우회전 → 분당구청 → 분당정보산업고교에서 좌회전 → 돌마교사거리에서 직진 → 아름다운 교회에서 좌회전 → 미금교 → 분당서울대학교병원
-
- 성수대교 방면
- 성수대교 → 구룡터널 → 분당내곡간 고속화도로(약 15분 직진) → 분당 도착해서 직진 → 분당구청 → 수내역 방향으로 우회전 → 정자역 → 분당정보산업고교에서 좌회전 → 돌마교사거리에서 직진 → 아름다운 교회에서 좌회전 → 미금교 → 분당서울대학교병원
-
- 청담대교 방면
- 청담대교 → 분당수서간 고속화도로(약 25분 직진) → 초림지하차도 → 정자지하차도(2번째 지하도) 지난 후 우측차선으로 빠짐 → 미금역 방향 → 미금역 방향으로 좌회전 → 돌마교사거리에서 우회전 → 700m정도 직진 → 아름다운 교회에서 좌회전 → 미금교 → 분당서울대학교병원
-
- 수원 IC 방면
- 수원 IC → 신갈오거리 → 신갈중학교 앞 → 구성삼거리 → 마북삼거리 → 보정교차로 → 죽전사거리 → 오리역 → 낙생교 지나자마자 우회전 → 미금교 → 분당서울대학교병원
-
- 수서역 SRT 방면
- 밤고개로(약 5분 직진) → 분당내곡간 고속화도로(약 10분 직진) → 분당 도착해서 직진 → 분당구청 → 수내역 방향으로 우회전 → 정자역 → 분당정보산업고교에서 좌회전 → 돌마교사거리에서 직진 → 아름다운 교회에서 좌회전 → 미금교 → 분당서울대학교병원
-
-
공지사항
공지사항
분당서울대학교병원의 공지사항을 알려드립니다.
-
건강정보
건강정보
다양하고 유익한 건강상식을 제공해 드립니다.
-
- 위암을 알면 예방이 보인다
- Theme Clinic 위암을 알면, 예방이 보인다 정리. 편집실 참고. 국가암지식정보센터, 보건복지부 국가암등록통계 등 검수. 소화기내과 최진주 교수 우리나라는 세계적으로 위암 발생률이 높은 국가로 알려져 있다. 식습관, 헬리코박터균 감염, 국가암검진 제도 등 한국만의 특수한 환경이 위암의 발생과 치료 성적 모두에 영향을 미치고 있다. 특히 위암은 초기 증상만으로 알아차리기 어려운 만큼 정기적인 검진을 통한 조기 발견이 중요하며, 헬리코박터균 제균 이후에도 꾸준한 생활습관 관리가 필요하다. 왜 한국에서 위암이 많이 발생할까 위암은 2023년 기준 국내 암 발생 순위 5위(남녀 전체)를 기록하고 있지만, 과거에는 오랜 기간 발생률 1위 암이었다. 여전히 동아시아 지역, 특히 한국·일본·중국에서 세계적으로 높은 발생률을 보이며, 우리나라 연간 신규 위암 환자는 약 2만 9,000명에 달한다. 발생률이 높은 첫 번째 이유는 헬리코박터 파일로리균 감염이다. 세계보건기구(WHO)는 이 균을 위암을 일으키는 1급 발암물질로 분류한다. 1980년대 국내 성인 감염률은 약 70%에 달했으며, 현재는 약 40% 수준으로 낮아졌다. 감염자는 비감염자보다 위암 위험이 약 2~3배 높은 것으로 알려져 있다. 식사를 따로 덜어 먹지 않고 찌개를 함께 나눠 먹는 식문화가 균 전파를 높이는 요인으로 지적되기도 한다. 두 번째 이유는 짜고 자극적인 전통 식습관이다. 김치, 젓갈, 장류 등 염분이 높은 음식은 위 점막을 자극해 위암 위험을 높인다. 국가암지식정보센터에 따르면 짠 음식을 많이 섭취하면 위암 위험이 최대 1~4배 증가하는 것으로 보고된다. 흡연과 음주 역시 위 점막 손상을 촉진하는 위험 요인이다. 헬리코박터균 감염 위암 위험 약 2~3배 증가 짠 음식 섭취 위암 위험 최대 1~4배 증가 흡연 위 점막 손상 촉진, 위암 위험 요인 음주 위 점막 자극, 위암 위험 요인 가족력 직계가족 위암 병력 시 위험 증가 위암, 증상보다 검진이 먼저다 위암은 증상만으로 조기에 알아차리기 어렵다. 초기에는 특별한 증상이 없는 경우가 많고, 소화불량이나 더부룩함 등이 나타나더라도 일상에서 흔히 경험하는 소화기 증상과 구분하기 어렵다. 반대로 이러한 증상이 있다고 해서 대부분 위암인 것도 아니다. 따라서 증상이 나타날 때까지 기다리기보다 정해진 시기에 검진을 받는 것이 중요하다. 우리나라 국가암검진에서는 만 40세 이상 남녀를 대상으로 2년마다 위암 검진을 시행하고 있으며, 특별한 증상이 없더라도 정기적인 검진을 통해 위암을 조기에 발견하는 것이 중요하다. 헬리코박터 제균 치료, 그 이후가 더 중요하다 헬리코박터 파일로리균 제균 치료는 위암 예방에 효과적인 방법으로 알려져 있으며, 1980년대 약 70%에 달했던 국내 감염률이 현재 약 40% 수준으로 낮아진 데에는 제균 치료 확대의 영향이 크다. 그러나 최근 제균 치료를 받은 뒤에도 위암이 발생하는 사례가 늘면서 새로운 주의가 요구된다. 분당서울대병원 소화기내과 신철민 교수 연구팀이 2010~2016년 국민건강보험공단 자료(128만 명)를 분석한 결과, 헬리코박터 제균 치료 이후에도 흡연·음주·복부비만 등 생활습관을 관리하지 않으면 위암 위험이 크게 상승하는 것으로 나타났다. 특히 55세 이후에 제균 치료를 받은 경우, 생활습관 악화에 따른 위암 위험 증가폭이 더욱 컸다. 연구팀은 “헬리코박터 제균 치료는 위암 위험을 유의미하게 낮추지만, 이를 위암으로부터 완전히 안전해지는 것으로 오해해서는 안 된다”며 “제균 이후에도 금연·금주·체중 관리에 힘쓰고, 특히 늦은 나이에 제균 치료를 받은 경우 위내시경 정기 검진을 반드시 유지해야 한다”고 강조했다. 위 건강을 지키기 위한 생활 수칙 위내시경 정기 검진 만 40세 이상이라면 2년마다 국가암검진을 활용하세요. 증상이 없어도 검진을 통해 조기 발견이 가능합니다. 헬리코박터 제균 후 관리 지속 제균 치료를 마쳤더라도 금연·절주·체중 관리는 반드시 이어가야 합니다. 제균이 위암 위험을 없애는 것은 아닙니다. 짠 음식·가공식품 줄이기 염분 과다 섭취는 위 점막을 자극합니다. 세계보건기구(WHO) 하루 나트륨 권고량(2,000mg)을 참고해 식습관을 점검하세요. 금연·절주 실천 흡연과 음주는 위 점막을 손상시키는 독립적 위험 요인입니다. 헬리코박터 제균 이후에도 마찬가지입니다. 경고 증상 확인 직계가족 중 위암 환자가 있거나 빈혈·흑색변·토혈, 원인 불명의 체중 감소, 지속적인 구토 등의 경고 증상이 있다면 전문의와 상담하세요.
-
- 췌장암 치료의 ‘개인 맞춤형 정밀 타격’ 시대를 열다
- Focus ② 소화기내과 황진혁 교수 췌장암 치료의 ‘개인 맞춤형 정밀 타격’ 시대를 열다 글. 박정혜 사진. 박성수 분당서울대병원 소화기내과 황진혁 교수 연구팀이 한국인 췌장암 환자 237명을 대상으로 대규모 유전체 분석을 수행하며, 치료 반응과 예후를 예측할 수 있는 정밀 의료 지표를 확보했다. 국내 최초의 시도로, 췌장암 치료를 개인 맞춤형 정밀 치료로 전환하는 중요한 분수령이 될 것으로 주목받고 있다. Q. 1 우리나라 췌장암 환자의 유전체 데이터를 확보한 의미는 무엇인가요? A. 1 암은 유전자 변이가 축적되면서 발생하는 질환입니다. 우리 몸의 세포는 분열할 때마다 약 30억 개에 달하는 염기서열을 복제하는데, 이 과정에서 어쩔 수 없이 오류가 발생합니다. 인체에는 이를 복구하는 시스템이 있지만, 나이가 들수록 변이는 조금씩 쌓이게 됩니다. 이러한 변이는 크게 두 가지로 나뉩니다. 태어날 때부터 가지고 있는 생식세포 변이와, 살아가면서 노화·흡연·자외선 등 환경적 요인에 의해 생기는 체세포 변이입니다. 이 두 가지 변이가 축적되어 중요한 암 관련 유전자에 영향을 미칠 때 암이 발생하게 됩니다. 지금은 이른바 ‘암 정밀치료 시대’입니다. 환자 개개인의 유전체 정보를 바탕으로 최적의 치료를 선택하는 정밀의료가 암 치료의 새로운 기준이 되고 있습니다. 그런데 정밀의료가 제대로 작동하려면 우리나라 환자의 데이터가 반드시 필요합니다. 우리나라 사람은 서구인과 인종적 특성과 생활환경이 다르기 때문에, 서구의 데이터를 그대로 적용하는 데는 한계가 있습니다. 그동안 국내 암 연구는 치료 중심의 임상 연구에 편중되어 있었고, 유전체 기반 연구를 위한 인프라는 상대적으로 부족했습니다. 최근 국가 차원에서 암과 희귀질환 유전체 데이터를 수집하고 있는 것도 바로 이러한 이유에서입니다. 췌장암은 서양에서도 다른 암에 비해 유전체 연구가 늦게 시작된 분야입니다. 치료가 어렵고 예후가 좋지 않다 보니 연구비와 인프라가 부족했기 때문입니다. 하지만 2010년대 초반, 기존 치료제의 새로운 조합이 췌장암에 효과가 있다는 사실이 알려지면서 치료 가능성에 대한 관심이 높아졌고, 이후 연구가 활발해졌습니다. 이번 연구는 국내에서도 정밀의료 기반 췌장암 치료의 출발점이 될 수 있다는 점에서 큰 의미를 갖습니다. Q. 2 이번 연구에서 발견된 췌장암의 특징과 예후와의 관계는 무엇인가요? A. 2 연구를 시작할 당시에는 서구와 유전적 차이가 상당할 것으로 예상했지만, 실제로는 큰 차이가 발견되지 않았습니다. 다만 주목할 만한 특징이 있었습니다. 간 전이가 동반된 환자에서 예후가 특히 좋지 않았는데, 이들 환자에서는 TP53 변이와 유전체 불안정성이 증가하고, 대표적인 암 유전자인 KRAS의 대립형질 불균형이 자주 관찰됐습니다. 암은 단순히 하나의 세포에서 시작해 동일한 세포들이 늘어나는 방식으로 자라지 않습니다. 암세포는 스스로 진화하면서 다양한 하위 집단을 형성합니다. 즉, ‘췌장암’이라는 이름은 같아도 환자마다 다르고, 같은 환자 안에서도 부위와 시간에 따라 그 성질이 달라집니다. 학교로 비유하자면, 같은 반 학생들이라도 개개인의 특성이 모두 다른 것과 같습니다. 이러한 결과는 특정 유전자 변이가 환자의 예후와 밀접하게 연관되어 있음을 보여주며, 환자별 치료 전략을 수립하는 데 중요한 단서가 됩니다. Q. 3 유전체 기반 치료가 실제 생존율 향상으로 이어질 수 있을까요? A. 3 췌장암 환자의 약 80~90%는 수술이 불가능한 3기 또는 4기에서 발견되기 때문에 생존율을 크게 끌어올리기는 쉽지 않은 것이 사실입니다. 하지만 유전체 기반 치료가 발전한다면 이들 환자에서도 3~5년 이상의 장기 생존을 기대할 수 있습니다. 실제로 미국에서 진행된 ‘Know Your Tumor’ 연구에서는 췌장암 환자를 대상으로 유전자 검사 결과를 바탕으로 맞춤 항암치료를 시행했을 때 생존 기간이 약 2배 증가한 것으로 보고된 바 있습니다(2020년, Lancet Oncology 발표). 표적이 있는 환자에게 그에 맞는 치료를 적용했을 때 예후가 뚜렷하게 개선된 것입니다. 이러한 흐름을 고려하면, 정밀의학의 발전이 췌장암 치료의 판도를 바꿀 가능성은 충분합니다. Q. 4 췌장암을 아형으로 나누는 이유와 치료 전략의 차이는 무엇인가요? A. 4 과거에는 같은 암이라면 동일한 성질을 가진다고 여겼습니다. 하지만 암세포는 환자마다 다를 뿐 아니라, 같은 환자 안에서도 암 덩어리 내부, 전이 부위, 그리고 치료가 진행되는 시간에 따라 끊임없이 진화합니다. 이렇듯 암은 고정된 존재가 아니라 변화하는 생태계에 가깝습니다. 유전체에 기반하여 암을 아형으로 나누는 이유는 바로 이 때문입니다. 아형에 따라 치료 반응과 예후가 달라지기 때문에, 각 유형에 맞는 치료 전략을 적용해야 효과를 기대할 수 있습니다. 현재까지의 연구를 종합하면 췌장암은 크게 Basal-like 타입과 Classical 타입으로 구분됩니다. 특히 Classical 타입은 폴피리녹스(FOLFIRINOX)와 같은 항암치료에 더 잘 반응하는 것으로 알려져 있으며, 이번 연구 결과도 이를 뒷받침합니다. 여기에 더해, DNA 복구 기능에 이상이 있는 HRD(상동재조합결핍) 특징을 가진 환자의 경우 백금 항암제가 포함된 폴피리녹스의 치료 효과가 더욱 좋았습니다. 아직 췌장암에서 HRD와 항암제 반응에 대한 대규모 데이터는 매우 부족한 상황이어서, 이번 연구의 의의가 더욱 큽니다. Q. 5 환자 맞춤형 치료가 실제 임상에서 적용되고 있는 단계인가요? A. 5 현재는 유전체 검사 결과를 얻기까지 몇 주의 시간이 소요되고, 췌장암에서 치료에 활용할 수 있는 ‘표적’이 발견될 확률도 높지 않아 처음부터 완전한 맞춤형 치료를 적용하기는 어렵습니다. 하지만 두 번째 치료 단계부터는 유전자 정보를 바탕으로 치료 전략을 조정하거나 임상시험에 참여하는 것이 가능합니다. 앞으로 연구가 축적되고 지금까지 알려지지 않았던 표적들이 새롭게 발굴된다면, 이를 겨냥한 치료제 개발로 이어질 수 있습니다. 개인 맞춤형 치료의 적용 범위는 점차 넓어질 것으로 기대됩니다. Q. 6 병원 시스템과 향후 연구 방향은 어떻게 준비되고 있나요? A. 6 현재 병원에서는 유전자 패널 검사(targeted NGS panel)를 기반으로 정밀의료를 시행하고 있습니다. 앞으로는 전장 유전체 분석(WGS)과 같은 고도화된 기술, 그리고 오르가노이드 분석 등 새로운 유전체 분석 플랫폼이 도입될 예정입니다. 유전체 분석 기술은 하루가 다르게 발전하고 있고, 임상에 적용되는 주기도 빠르게 짧아지고 있습니다. 이러한 흐름에 발맞추어 병원 시스템 차원에서 선도적으로 새로운 기술을 도입하고 전문 인력을 양성하는 것이 정밀의료의 안정적인 정착을 위한 핵심 과제입니다. 향후 연구에서는 암 미세환경(TME)에 특히 주목할 계획입니다. 암세포를 둘러싼 면역세포, 그리고 종양 내 미생물과의 상호작용을 분석함으로써, 왜 췌장암에서 면역세포가 제 기능을 발휘하지 못하는지, 어떻게 하면 면역이 활성화된 환경으로 전환할 수 있는지를 규명할 것입니다. 또한 혈액 내 대사체, 단백질, mRNA 등을 이용한 액체생검 기반 조기 진단 기술 개발도 중요한 연구 과제입니다. 액체생검은 혈액 속에 극미량으로 존재하는 암세포의 흔적, 즉 순환종양 DNA를 찾아내는 기술입니다. 과거에는 그 양이 워낙 적어 검출이 어려웠지만, 과학기술의 발전으로 점차 가능해지고 있습니다. 영상 데이터를 인공지능으로 분석해 조기 이상 징후를 포착하는 연구도 병행되고 있습니다. 아직 갈 길이 있지만, 언젠가는 건강검진처럼 간편하게 췌장암을 조기에 발견할 수 있는 날이 올 것으로 기대합니다. Q. 7 췌장암 환자와 보호자에게 전하고 싶은 메시지는 무엇인가요? A. 7 췌장암은 여전히 예후가 좋지 않은 질환이지만, 5년 생존율은 과거에 비해 2배 이상 향상되었습니다. 국내외에서 기초·중개·임상 연구가 활발히 이루어지고 있고, 이 분야를 연구하는 전문가도 꾸준히 늘고 있습니다. 특히 희망적인 것은 췌장암에서 가장 흔한 유전자 변이인 KRAS를 표적으로 하는 치료제 개발입니다. 40여 년간 난공불락으로 여겨졌던 KRAS를 겨냥한 항암제가 최근 속속 개발되고 있으며, KRAS G12C를 시작으로 G12D 등 다양한 변이 아형에 대한 치료제의 임상시험이 진행 중입니다. 조기에 발견하고 적절한 치료를 이어간다면, 앞으로 더 많은 환자에게 새로운 가능성이 열릴 것입니다. TIP 1 췌장암 정밀의료가 중요한 이유 췌장암은 환자마다 유전자 변이와 종양 특성이 다르기 때문에, 동일한 치료로는 충분한 효과를 기대하기 어렵다. 유전체 분석을 통해 환자의 암 특성을 정확히 파악하면 보다 효과적인 치료 전략을 선택할 수 있으며, 장기적으로는 생존율 향상에도 기여할 수 있다. TIP 2 췌장암 예방과 관리에서 중요한 생활 습관 췌장암 유전자 변이는 환경과 생활 습관의 영향을 받기도 한다. 규칙적인 운동, 스트레스 관리, 균형 잡힌 식습관은 기본적인 예방의 출발점이다. 검증되지 않은 건강보조식품에 의존하기보다, 의학적으로 검증된 치료와 꾸준한 생활 관리가 훨씬 중요하다는 점을 기억하자. 소화기내과 황진혁 교수 의료진 소개 바로가기 >>
-
- 바로가기
- 정보공개
- 고객의 소리
본문
페이스북
트위터
- [ 혈액종양내과 (두경부암센터) ]
- 위암, 대장암, 두경부암의 항암화학요법, 고형암의 임상시험
진료시간표
| 요일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 오전 |  |
|
||||
| 오후 | |
 |
||||
|
||||||
분당서울대학교병원 종양내과에 근무하고 있는 이근욱입니다. 종양내과 의사는 암환자의 상태를 포괄적으로 평가하고, 가장 적합한 치료 방법을 제시해 주며, 가장 적합한 항암화학요법을 최소한의 부작용으로 시행받을 수 있도록 도와 드리는 역할을 담당합니다. 저는 위장관에서 발생한 암종들(위암, 대장암 등) 및 두경부암의 치료를 주로 담당하고 있습니다.
최근의 암치료 방법은 급진적으로 발전하고 있습니다. 한 명의 의사가 환자의 치료를 독단적으로 결정하기에는 이미 관련분야의 지식이 너무 광범위해서 한계가 있는 실정이며, 각 분야의 의사들이 최신의 지식을 공유하여 토론한 후 가장 적합한 치료법을 정하는 ‘다학제적 치료방법 결정’이 암치료의 추세라고 할 수 있습니다. 분당서울대학교 위암, 대장암, 두경부암팀은 이미 개원 당시부터 다학제 팀(multi-disciplinary team)을 구성하여 환자분들께 최선의 치료를 제공하고 있습니다. 또한, 종양내과에서는 적합한 환자들께는 최신의 임상 시험에 참여하여 치료 받을 수 있는 기회도 제공하고 있습니다.
진료 현장에서 만나뵙는 암으로 고통받고 있는 많은 환자분들께 최고의 지식과 열정으로 암을 극복해 나가는데 도움을 드리도록 최선을 다하겠습니다.
위암, 대장암, 두경부암의 항암화학요법
- 우리나라에서 위암은 가장 흔한 암이며, 대장암의 경우도 생활습관의 서구화에 따라 그 발생률이 급격히 증가하고 있습니다. 위암 및 대장암의 경우 완치적 절제술 후 재발방지를 위한 보조항암화학요법을 추가로 시행하는 것이 완치율을 향상시키는 것으로 확실히 증명되어 있습니다. 또한 전이성 암의 경우라 할지라도 적절한 항암화학요법을 통하여 삶의 연장 및 삶의 질을 향상시킬 수 있습니다. 특히 대장암의 경우에는 원격전이가 동반되었다 할지라도 ‘전이 절제술 (전이 병소를 제거하는 수술)’ 및 항암화학요법을 병용할 경우 상당수의 환자에서 완치를 기대할 수 있습니다.
- 두경부암의 경우, 흔하지는 않지만 항암화학요법 및 방사선치료 또는 수술을 병용할 경우 상당수에서 완치를 기대할 수 있습니다. 비록 치료 과정이 쉽지는 않으나, 경험있는 의료진의 도움을 통하여 많은 분들이 좋은 결과를 얻을 수 있는 암종입니다.
- 위암/대장암을 포함한 소화기 계통의 암과 두경부암은 외과(이비인후과), 방사선종양학과, 종양내과 및 여러 관련 의사들(소화기내과, 영상의학과, 병리학과 등)의 긴밀한 소통과 협진이 있어야만 더 좋은 치료 성적을 얻을 수 있습니다. 분당서울대병원 위암, 대장암, 두경부암팀은 조화로운 다학제적 협력을 통해서 최선의 치료를 제공해 드립니다.
고형암의 임상시험 (항암화학요법)
- 암치료의 방법은 매우 빨리 발전하고 있습니다. 이러한 발전은 환자들을 대상으로 한 ‘임상시험’을 통하여 이루어집니다. 특히, 새로운 항암제가 개발되어 시판되기까지 많은 임상시험의 과정을 거쳐야 합니다. 환자들께서는 임상시험을 통해서 최신의 치료방법을 접할 수 있으며 더 좋은 효과를 기대해 볼 수 있습니다. 하지만, 새로운 치료법이니만큼 부작용에 대하여 좀더 면밀한 관찰도 요구됩니다. 분당서울대학교병원 종양내과 의료진들은 임상시험에 많은 숙달된 경험을 가지고 있으며, 임상시험 수행을 통하여 새로운 암 치료법 개발에 많은 노력을 기울이고 있습니다.
직위 ●
- 서울의대 & 분당서울대학교병원 내과 (혈액종양내과; 정년보장 교수) 교수
- 분당서울대학교병원 (2024년 7월~현재) 암센터장
학력 ●
- 2007 서울대학교 의학대학원 (분자종양학) 의학 박사
- 2004 서울대학교 의학대학원 (내과학) 의학 석사
- 1998 서울대학교 의과대학 의학 학사
경력 ●
- 2024 - 현재 분당서울대학교병원 암센터장
- 2020 - 2026 분당서울대학교병원 임상시험센터장
- 2018 - 현재 서울의대 & 분당서울대학교병원 혈액종양내과 교수
- 2016 - 2020 분당서울대학교병원 혈액종양내과 분과장
- 2013 - 2018 서울의대 & 분당서울대학교병원 혈액종양내과 부교수
- 2012 - 2013 MD Anderson Cancer Center Department of Systems Biology 방문교수
- 2005 - 2013 분당서울대학교병원 혈액종양내과 임상교수
- 2004 - 2005 서울대학교병원 혈액종양내과 전임의
- 2000 - 2004 서울대학교병원 내과 전공의
수상 ●
- 2017 머크-세르노 대장암 학술상 (대한종양내과학회 (KSMO))
- 2013 보령 암학술상 (대한종양내과학회 (KSMO))
- 2011 한미 우수 구연상 (대한종양내과학회 (KSMO))
- 2010 송암 학술상 (한국혈전지혈학회 (KSTH))
- 2009 보령 암학술상 (대한종양내과학회 (KSMO))
활동 ●
- 2025 대한항암요법연구회(KCSG) 위암분과 위원장 (2025년~현재)
- 2024 대한암학회 (KCA) 총무이사 (2024년 7월~현재)
- 2024 제10기 중증(암)질환심의위원회 위원 (건강보험심사평가원; 2024년 2월~현재)
- 2017 대한항암요법연구회(KCSG) 위암분과 간사 (2017년~2025년)
- 대한종양내과학회 (KSMO), 대한암학회 (KCA), 대한항암요법연구회 (KCSG), 한국혈전지혈학회(KSTH), 대한내과학회 정회원
- 미국종양내과학회 (ASCO), 유럽종양내과학회 (ESMO), 미국암연구학회(AACR) 정회원
논문 ●
-
Jin Won Kim, Jung-Yeon Choi, Woochan Park, Minsu Kang, Jeongmin Seo, Eun Hee Jung, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Sang-A Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang, Kwang-Il Kim, Jee Hyun Kim
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital.
Cancer Res Treat
2025 ;58 (1) :329 -338
-
Sung-Hyun Hwang, Mingyun Bae, Ji-Won Kim, Seung Yoon Hyun, Kui-Jin Kim, Joshua H Choe, Min Jung Kim, Ji Won Park, Seung-Yong Jeong, Songji Choi, Woochan Park, Jeongmin Seo, Heejung Chae, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Haeseong Park, Andrew J Aguirre, Eunjung Alice Lee, Ja-Lok Ku, Keun-Wook Lee
VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation.
bioRxiv
2025
-
Minsu Kang, Kui-Jin Kim, Ji Hea Sung, Milang Nam, Sung-Hyun Hwang, Woochan Park, Jeongmin Seo, Eun Hee Jung, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Keun-Wook Lee
Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With PIK3CA Mutations and Overcoming Strategies.
Anticancer Res
2025 ;45 (5) :1877 -1896
-
Sung-Hyun Hwang, Ji-Won Kim, Haeseong Park, Andrew J Aguirre, Kui-Jin Kim, Songji Choi, Woochan Park, Jeongmin Seo, Heejung Chae, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Keun-Wook Lee
COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer.
Gastric Cancer
2025 ;28 (6) :1144 -1157
-
Jaffer A Ajani, Maria Alsina, Markus Moehler, Keun-Wook Lee, Wenxi Tang, Jason Steenkamp, Emily Prentiss, Kaijun Wang, Becky Hooper, Lin Zhan
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis.
Gastric Cancer
2025 ;28 (6) :1021 -1032
-
Eun-Jeong Jeong, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee, Soo-Mee Bang, Ji Yun Lee
Prognostic impact of GNRI-IPI score in octogenarians with diffuse large B-Cell lymphoma treated with R-CHOP.
Ann Hematol
2025 ;104 (11) :5867 -5879
-
Jeongmin Seo, Min Joo Kim, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee, Sun Wook Cho, Jae Hoon Moon
Reversibility of immune checkpoint inhibitor-induced hypothyroidism.
Endocr Relat Cancer
2025 ;32 (11)
-
S Hwang, M H Hong, S H Shin, T Yun, K-W Lee, J H Kim, M J Ahn, B Keam, H W Lee, M K Kim, H J Yun, Y Kim, H J Kim, S H Cho, H J An, S Y Oh, S-G Park, Y W Koh, H K Ahn, J H Kwon, Y-G Lee, K-U Park, I G Hwang, S-B Kim, S Kim, H R Kim, KCSG TRIUMPH investigators
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial).
ESMO Open
2025 ;10 (10) :105772 -105772
-
Kyoo Hyun Kim, Shinwon Hwang, Min Kyoung Kim, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Joo Hang Kim, Bhumsuk Keam, Byoung Chul Cho, So Yeon Oh, Sang Hee Cho, Sangwoo Kim, Sung-Bae Kim, Min Hee Hong, Hye Ryun Kim
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial.
Cancer Res Treat
2025 ;57 (4) :968 -980
-
Jiwon Park, Ji-Won Kim, Jin Hyun Nam, Youngjune Kim, Jin Won Kim, Suin Kang, Yejee Lim, Kyungim Kim, Keun-Wook Lee
Comparative analysis of osteoporotic versus pathologic fracture in metastatic colorectal cancer patients.
Osteoporos Int
2025 ;36 (10) :1941 -1950
-
Keun-Wook Lee, Dae Young Zang, Hyung-Don Kim, Jin-Won Kim, Bum Jun Kim, Yoon-Koo Kang, Min-Hee Ryu, Hark Kyun Kim
Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
Br J Cancer
2025 ;133 (2) :208 -215
-
Eun Joo Kang, Shinwon Hwang, Yun-Gyoo Lee, Jong-Kwon Choi, Seong Hoon Shin, Yoon Hee Choi, Keun-Wook Lee, Hyun Woo Lee, Min Kyoung Kim, Seung Taek Lim, Hwan Jung Yun, Sang-Gon Park, Sangwoo Kim, Sung-Bae Kim, Hye Ryun Kim
Clinical Impact of TP53 Mutations in Patients with Head and Neck Cancer Who Were Treated with Targeted Therapies or Immunotherapy.
Cancer Res Treat
2025 ;57 (3) :709 -719
-
Elena Elimova, Jaffer Ajani, Howard Burris, Crystal S Denlinger, Syma Iqbal, Yoon-Koo Kang, Jwa Hoon Kim, Keun-Wook Lee, Bruce Lin, Rutika Mehta, Do-Youn Oh, Sun Young Rha, Young Mi Seol, Lin Yang, Mark A Ozog, Phillip M Garfin, Geoffrey Ku
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
Lancet Oncol
2025 ;26 (7) :847 -859
-
Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim, Do-Youn Oh, Hope Uronis, Sun Jin Sym, Mohamad Sonbol, Khaldoun Almhanna, Mohamedtaki A Tejani, Beodeul Kang, Michael H Kagey, Melissa Stilian, Calvin Jia, Cynthia A Sirard, Rachel Altura, Jaffer A Ajani, Samuel J Klempner
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Nat Commun
2025 ;16 (1) :6393 -6393
-
Ji Yun Lee, Ju-Hyun Lee, Eun-Jung Jung, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang
Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study.
Cardiovasc Diabetol
2025 ;24 (1) :276 -276
-
Ji-Won Kim, Dong Soo Kyung, Won Yeong Ko, Hwang-Phill Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Keun-Wook Lee
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer.
Gastric Cancer
2025 ;28 (4) :620 -630
-
Marcia Cruz-Correa, Rui-Hua Xu, Markus Moehler, Do-Youn Oh, Ken Kato, David Spigel, Hendrik-Tobias Arkenau, Josep Tabernero, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Hidekazu Hirano, Lucjan Wyrwicz, Roberto Pazo Cid, Hui Xu, Tao Sheng, Gisoo Barnes
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.
Curr Med Res Opin
2025 ;41 (6) :1007 -1016
-
Seo Yoon Jang, Yun-Gyoo Lee, Sang Hoon Chun, Ji Hyun Park, Keon Uk Park, Hyun Chang, Keun-Wook Lee, Hye Ryun Kim, Seong Hoon Shin, Ho Jung An, Kyoung Eun Lee, In Gyu Hwang, Myung-Ju Ahn, Sung-Bae Kim, Bhumsuk Keam
Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma.
Head Neck
2025 ;47 (6) :1621 -1630
-
Ji Yun Lee, Kui-Jin Kim, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Tae Min Kim, Jin Ho Paik
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma.
Blood Cancer J
2025 ;15 (1) :108 -108
-
Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, Pamela N Munster, Yanhong Deng, Gary Richardson, Dong Yan, Myung-Ah Lee, Keun-Wook Lee, Hongming Pan, Steven Hager, Xingya Li, Shaozhong Wei, Xinfang Hou, Craig Underhill, Michael Millward, Ina Nordman, Jingdong Zhang, Jianzhen Shan, Guohong Han, Jaspreet Grewal, Shirish M Gadgeel, Rachel E Sanborn, Seok Jae Huh, Xiaohua Hu, Yihong Zhang, Ziyong Xiang, Laisheng Luo, Xiaoxi Xie, Zhe Shi, Yaolin Wang, Ling Zhang, Feng Wang, Rui-Hua Xu
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Signal Transduct Target Ther
2025 ;10 (1) :189 -189
-
Jieun Lee, In Hee Kim, Donghyeok Seol, Sangjun Lee, Mira Yoo, Tae-Kyeong Lee, So Hee Yoon, Eunju Lee, Duyeong Hwang, So Hyun Kang, Young Suk Park, Bosung Ku, Sang Youl Jeon, Yongmun Choi, Keehoon Jung, Ji-Won Kim, Jin Won Kim, Sang-Hoon Ahn, Keun-Wook Lee, Hyung-Ho Kim, Hyeon Jeong Oh, Dong Woo Lee, Yun-Suhk Suh
High-Throughput Chemotherapeutic Drug Screening System for Gastric Cancer (Cure-GA).
Ann Surg Oncol
2025 ;32 (5) :3781 -3795
-
Markus Moehler, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Keun-Wook Lee, Sun Young Rha, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Lucjan Wyrwicz, Umut Disel, Roberto A Pazo-Cid, Lorenzo Fornaro, Yaling Xu, Tao Sheng, Silu Yang, Alysha Kadva, Marcia Cruz-Correa, Rui-Hua Xu
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression?≥?1%: A Retrospective Analysis of RATIONALE-305.
Adv Ther
2025 ;42 (5) :2248 -2268
-
Funda Meric-Bernstam, Sun Young Rha, Erika Hamilton, Yoon-Koo Kang, Diana L Hanna, Syma Iqbal, Keun-Wook Lee, Jeeyun Lee, Muralidhar Beeram, Do-Youn Oh, Jorge Chaves, Rachel A Goodwin, Jaffer A Ajani, Lin Yang, Rajen Oza, Elena Elimova
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.
Nat Commun
2025 ;16 (1) :4293 -4293
-
Taroh Satoh, Philippe Barthelemy, Lucia Nogova, Kazunori Honda, Hidekazu Hirano, Keun-Wook Lee, Sun Young Rha, Min-Hee Ryu, Joon Oh Park, Toshihiko Doi, Jaffer Ajani, Nanae Hangai, Jill Kremer, Mark Mina, Mei Liu, Kohei Shitara
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.
Eur J Cancer
2025 ;218 :115262 -115262
-
Nick Pavlakis, Kohei Shitara, Katrin Sjoquist, Andrew Martin, Anthony Jaworski, Niall Tebbutt, Yung-Jue Bang, Thierry Alcindor, Chris O'Callaghan, Andrew Strickland, Sun Young Rha, Keun-Wook Lee, Jin-Soo Kim, Li-Yuan Bai, Hiroki Hara, Do-Youn Oh, Sonia Yip, John Zalcberg, Tim Price, John Simes, David Goldstein
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
J Clin Oncol
2025 ;43 (4) :453 -463
-
S J Klempner, R A Pazo-Cid, S Lonardi, L Swanson, M J Arango, P Enzinger, A H Ko, G M Vaccaro, K Yamaguchi, A Saeed, K-W Lee, K Shitara, D Ilson, J A Ajani, R Fuldeore, S Braun, M S Broder, M A Shah
Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab?+ chemotherapy: a RAND/UCLA modified Delphi panel study.
ESMO Gastrointest Oncol
2025 ;7 :100131 -100131
-
Tae-Han Kim, Ichiro Uyama, Sun Young Rha, Maria Bencivenga, Jiyeong An, Lucjan Wyrwicz, Dong-Hoe Koo, Richard van Hillegersberg, Keun-Wook Lee, Guoxin Li, Takaki Yoshikawa, Brian Badgwell, Sylvie Lorenzen, In-Ho Kim, In-Seob Lee, Hye-Sook Han, Hur Hoon
Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024.
J Gastric Cancer
2025 ;25 (1) :133 -152
-
Jin Won Kim, Hee Young Na, Sejoon Lee, Ji-Won Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jaihwan Kim, Jin-Hyeok Hwang, Kihwan Hwang, Chae-Yong Kim, Yong Beom Kim, Soomin Ahn, Kyu Sang Lee, Hyojin Kim, Hye Seung Lee, So Yeon Park, Gheeyoung Choe, Jee Hyun Kim, Jin-Haeng Chung
Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital.
Sci Rep
2025 ;15 (1) :2171 -2171
-
Jeong Hwan Lee, Nayoung Kim, Ji-Hyun Kim, Hyeon Jeong Oh, Yeejin Kim, Yonghoon Choi, Hyemin Jo, Ho-Kyoung Lee, Jinju Choi, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hye Seung Lee, So Hyun Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Soyeon Ahn
Clinicopathological Factors Influencing PD-L1 Expression and the Effect of Immune Checkpoint Inhibitors on Survival Outcomes in Patients with Gastric Cancer Depending on Sex in a Tertiary Hospital in South Korea.
Cancer Res Treat
2025 ;58 (3) :860 -871
-
Songji Choi, Se Hyun Kim, Sejoon Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study.
Cancer Res Treat
2024 ;57 (1) :70 -82
-
Narikazu Boku, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Kensei Yamaguchi, Ken Kato, Shigenori Kadowaki, Kunihiro Tsuji, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Sun Young Rha, Ik-Joo Chung, Sun Jin Sym, Li-Tzong Chen, Jen-Shi Chen, Li-Yuan Bai, Takashi Nakada, Shunsuke Hagihara, Reina Makino, Eiji Nishiyama, Yoon-Koo Kang, Keun-Wook Lee
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3?trial.
Gastric Cancer
2024 ;27 (6) :1287 -1301
-
Yoon-Koo Kang, Shukui Qin, Sang Cheul Oh, In-Ho Kim, Jong Gwang Kim, Yong Li, Zhuchen Yan, Jin Li, Li-Yuan Bai, Catherine Chan, Akeem Yusuf, Anita Zahlten-Kumeli, Kate Taylor, Kensei Yamaguchi, Keun-Wook Lee
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis.
Gastric Cancer
2024 ;27 (5) :1046 -1057
-
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Jufeng Wang, Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, Rui-Hua Xu, RATIONALE-305 Investigators, Keun-Wook Lee
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
BMJ
2024 ;385 :e078876 -e078876
-
Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn, Keun-Wook Lee
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials.
Cancer Res Treat
2024 ;56 (4) :1068 -1076
-
W I Wan Zamaniah, Y Narita, I Nakayama, T Yoshino, K Shitara, H Shoji, M Ng, W P Yong, S O Wardhani, K-W Lee, S Y Rha, V Krishna, T Fleitas, A Cervantes, M Basade, H Kawakami, F Wang, C Ishioka, E Baba, K H Yeh, E Smyth, M-H Chen, J Li, R R Pribadi, E Sirachainan, P Sunpaweravong, D L Sacdalan, G Pentheroudakis, M N Ibtisam, G Curigliano, A Lui, J L Peneyra
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.
ESMO Open
2024 ;9 (2) :102226 -102226
-
Anita Zahlten-Kumeli, Kate Taylor, Yoon-Koo Kang, Sang Cheul Oh, Erika Hitre, Haci Mehmet Turk, Raquel Guardeno Sanchez, Peter C Enzinger, Giovanni Gerardo Cardellino, Jin Li, In-Ho Kim, Zev A Wainberg, Kensei Yamaguchi, Alexandra Teixeira, Adrian A Udrea, Shukui Qin, Keun-Wook Lee, Anwaar Saeed
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Gastric Cancer
2024 ;27 (3) :558 -570
-
Ludovic Evesque, Michael Schenker, Min-Hee Ryu, Yoon-Koo Kang, Arlo McGinn, Yufan Zhao, Jennifer Lee, Maria Di Bartolomeo, Anna Kryzhanivska, Lucjan Wyrwicz, Sang Chul Oh, Jong Gwang Kim, Harry Yoon, Atsuo Takashima, Narikazu Boku, Ian Chau, Keun-Wook Lee, Yee Chao
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer
2024 ;27 (2) :375 -386
-
Hye Sook Han, Keun-Wook Lee
Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer.
J Gastric Cancer
2024 ;24 (1) :4 -28
-
Hyun Woo Lee, Yun-Gyoo Lee, Keun-Wook Lee, Bhumsuk Keam, Jin-Soo Kim, Myung-Ju Ahn, Hee Kyung Ahn, Ho Jung An, Kyoo Hyun Kim, Sun Min Lim, Hye Ryun Kim
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial.
Cancer Res Treat
2024 ;56 (1) :37 -47
-
Songji Choi, Minsu Kang, Ji-Won Kim, Jin Won Kim, Jae Hyun Jeon, Heung-Kwon Oh, Hae Won Lee, Jai Young Cho, Duck-Woo Kim, Sukki Cho, Jee Hyun Kim, Kwhanmien Kim, Sung-Bum Kang, Sanghoon Jheon, Keun-Wook Lee
Long-term clinical outcomes after the second metastasectomy in patients with resected metastatic colorectal cancer.
Curr Probl Cancer
2024 ;53 :101151 -101151
-
Eun Hee Jung, Yusuke Hiratsuka, Sang-Yeon Suh, Seok-Joon Yoon, Beodeul Kang, Si Won Lee, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Yu Jung Kim
Clinicians' Prediction of Survival Is Most Useful for Palliative Care Referral.
Palliat Med Rep
2024 ;5 (1) :365 -372
-
Sung-Woo Cho, Bhumsuk Keam, Keun-Wook Lee, Ji-Won Kim, Doo Hee Han, Hyun Jik Kim, Jeong-Whun Kim, Dong-Young Kim, Chae-Seo Rhee, Yun Jung Bae, Ji-Hoon Kim, Keun-Yong Eom, Hong-Gyun Wu, Yong Hwy Kim, Chae-Yong Kim, Sun Ha Paek, Hyojin Kim, Tae-Bin Won
Role of induction chemotherapy in advanced-stage olfactory neuroblastoma.
Int Forum Allergy Rhinol
2024 ;14 (12) :1882 -1891
-
Ji Yun Lee, Ju-Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee, Soo-Mee Bang
Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study.
J Korean Med Sci
2024 ;39 (22) :e175 -e175
-
Seung-Been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Nak-Jung Kwon, Keun-Wook Lee
Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy.
Cancer Res Treat
2024 ;56 (4) :1171 -1182
-
Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, Minsu Kang, Minkyu Jung, Sun Young Rha
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
BMC Cancer
2024 ;24 (1) :252 -252
-
Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim, Yong Sang Hong, Seung-Hoon Beom, Yongjun Cha, Yoonjung Choi, Seonhui Kim, Yung-Jue Bang
A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer.
Cancer Res Treat
2024 ;56 (2) :590 -601
-
Songji Choi, Seyoung Seo, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jwa Hoon Kim, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Sang-We Kim, Dae Ho Lee, Jae Cheol Lee, Chang-Min Choi, Shinkyo Yoon, Su-Jin Koh, Young Joo Min, Yongchel Ahn, Hwa Jung Kim, Jin Ho Baek, Sook Ryun Park, Jee Hyun Kim
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study.
Cancer Res Treat
2024 ;56 (2) :404 -413
-
Sujin Oh, Soo Kyung Nam, Keun-Wook Lee, Hye Seung Lee, Yujun Park, Yoonjin Kwak, Kyu Sang Lee, Ji-Won Kim, Jin Won Kim, Minsu Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim
Genomic and Transcriptomic Characterization of Gastric Cancer with Bone Metastasis.
Cancer Res Treat
2024 ;56 (1) :219 -237
-
Ji-Hyun Kim, Nayoung Kim, Du Hyun Song, Yonghoon Choi, Eun-Bi Jeon, Sihyun Kim, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hyeon Jeong Oh, Hye Seung Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Soyeon Ahn
Sex-dependent different clinicopathological characterization of Epstein-Barr virus-associated gastric carcinoma: a large-scale study.
Gastric Cancer
2024 ;27 (2) :221 -234
-
Du Hyun Song, Nayoung Kim, Hyeong Ho Jo, Sangbin Kim, Yonghoon Choi, Hyeon Jeong Oh, Hye Seung Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, So Hyun Kang, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Soyeon Ahn, Young-Joon Surh
Analysis of Characteristics and Risk Factors of Patients with Single Gastric Cancer and Synchronous Multiple Gastric Cancer among 14,603 Patients.
Gut Liver
2024 ;18 (2) :231 -244
-
Ji Yun Lee, Ju-Hyun Lee, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang
The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients.
Cancer Res Treat
2024 ;57 (2) :612 -620
-
Yonghoon Choi, Nayoung Kim, Chang Yong Yun, Yoon Jin Choi, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Sang-Hoon Ahn, Do Joong Park, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Dong Ho Lee, Hyung-Ho Kim
Correction: Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15?years.
Gastric Cancer
2023 ;26 (5) :843 -845
-
Hyeong Ho Jo, Nayoung Kim, Hyeon Jeong Oh, Du Hyun Song, Yonghoon Choi, Jaehyung Park, Jongchan Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hye Seung Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Soyeon Ahn
The Clinicopathological Features of Mixed Carcinoma in 7,215 Patients with Gastric Cancer in a Tertiary Hospital in South Korea.
Gut Liver
2023 ;17 (5) :731 -740
-
Daniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, Keun-Wook Lee, Matthew Ch Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy, Howard S Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A Marrone, Ronan J Kelly, Rosalyn A Juergens, Jong Gwang Kim, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, Do-Youn Oh, Jennifer Yen, Justin I Odegaard, Errin Lagow, Daner Li, Jichao Sun, Patrick Kaminker, Paul A Moore, Minori Koshiji Rosales, Haeseong Park
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Oncology (Williston Park)
2023 ;37 (4) :176 -183
-
Seon-Hye Won, Yusuke Hiratsuka, Sang-Yeon Suh, Hayoung Bae, Sung-Eun Choi, Yu Jung Kim, Beodeul Kang, Si Won Lee, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee
Mid-upper Arm Circumference as an Indicator of Quality of Life of Patients with Advanced Cancer.
J Palliat Care
2023 ;38 (1) :24 -29
-
Hironaga Satake, Keun-Wook Lee, Hyun Cheol Chung, Jeeyun Lee, Kensei Yamaguchi, Jen-Shi Chen, Takaki Yoshikawa, Kenji Amagai, Kun-Huei Yeh, Masahiro Goto, Yee Chao, Ka-On Lam, Shi Rong Han, Shinichi Shiratori, Sukrut Shah, Kohei Shitara
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Jpn J Clin Oncol
2023 ;53 (3) :221 -229
-
Jieun Yang, Se Hyun Kim, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Thorac Cancer
2023 ;14 (1) :52 -60
-
Sun-Wook Kim, Jung Hun Ohn, Nak-Hyun Kim, Eun Sun Kim, Yejee Lim, Jongchan Lee, Hye Won Kim, Jiwon Ryu, Hee-Sun Park, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee, Hak Chul Jang
The Hospitalist-Oncologist co-ManagemEnt (HOME) system improves hospitalization outcomes of patients with cancer.
BMC Health Serv Res
2023 ;23 (1) :1367 -1367
-
Hyeong Ho Jo, Nayoung Kim, Jieun Jang, Yonghoon Choi, Jaehyung Park, Young Mi Park, Soyeon Ahn, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hyeon Jeong Oh, Hye Seung Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim
Impact of Body Mass Index on Survival Depending on Sex in 14,688 Patients with Gastric Cancer in a Tertiary Hospital in South Korea.
Gut Liver
2023 ;17 (2) :243 -258
-
Tae Hyun Kim, Yoonjin Kwak, Changhoon Song, Hye Seung Lee, Duck-Woo Kim, Heung-Kwon Oh, Jin Won Kim, Keun-Wook Lee, Sung-Bum Kang, Jae-Sung Kim
GLUT-1 may predict metastases and death in patients with locally advanced rectal cancer.
Front Oncol
2023 ;13 (0) :1094480 -1094480
-
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hyo Jung Kim, Hwan Jung Yun
Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01).
Cancers (Basel)
2023 ;15 (2)
-
Hyun Jung Kwon, Yujun Park, Soo Kyung Nam, Enoch Kang, Ka-Kyung Kim, Inhae Jeong, Yoonjin Kwak, Jeesun Yoon, Tae-Yong Kim, Keun-Wook Lee, Do-Youn Oh, Seock-Ah Im, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Hyung-Ho Kim, Han-Kwang Yang, Hye Seung Lee
Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
Cancer Med
2023 ;12 (9) :10371 -10384
-
Jiyun Lee, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Seyoung Seo, Sung-Bae Kim, Ji-Won Kim, Keun-Wook Lee, Eun Joo Kang, Ju Won Kim, Yoon Ji Choi, Byoung-Yong Shim, Ho-Jung An, Lee Chun Park, Seong Hoon Shin, Jae-Joon Kim, So Yeon Oh, Min Kyoung Kim, Myung-Ju Ahn
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Cancer
2023 ;129 (19) :2966 -2974
-
Do-Youn Oh, Maria Alsina Maqueda, David I Quinn, Peter J O'Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P Dean, Hendrik-Tobias Arkenau
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
2023 ;23 (1) :1056 -1056
-
Dong Hyun Kim, Yoojoo Lim, Chan-Young Ock, Gahee Park, Seonwook Park, Heon Song, Minuk Ma, Mohammad Mostafavi, Eun Joo Kang, Myung-Ju Ahn, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Sung-Bae Kim, Bhumsuk Keam
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma.
Head Neck
2023 ;45 (12) :3086 -3095
-
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M Sjoquist, Andrew J Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J O'Callaghan, Niall C Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
2023 ;23 (1) :180 -180
-
Koung Jin Suh, Min-Hee Ryu, Dae Young Zang, Woo Kyun Bae, Hye Seung Lee, Hyeon Jeong Oh, Minsu Kang, Ji-Won Kim, Bum Jun Kim, Peter G S Mortimer, Hee Jung Kim, Keun-Wook Lee
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Oncologist
2023 ;28 (9) :e823 -e834
-
Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
Cancer Res Treat
2023 ;55 (4) :1250 -1260
-
Yoojoo Lim, Songji Choi, Hyeon Jeong Oh, Chanyoung Kim, Sanghoon Song, Sukjun Kim, Heon Song, Seonwook Park, Ji-Won Kim, Jin Won Kim, Jee Hyun Kim, Minsu Kang, Sung-Bum Kang, Duck-Woo Kim, Heung-Kwon Oh, Hye Seung Lee, Keun-Wook Lee
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes for prediction of prognosis in resected colon cancer.
NPJ Precis Oncol
2023 ;7 (1) :124 -124
-
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
J Clin Oncol
2023 ;41 (4) :816 -825
-
Samuel J Klempner, Keun-Wook Lee, Kohei Shitara, Jean-Phillippe Metges, Sara Lonardi, David H Ilson, Nicola Fazio, Tae Yong Kim, Li-Yuan Bai, Diarmuid Moran, Jianning Yang, Ahsan Arozullah, Jung Wook Park, Jeffrey J Raizer, Yung-Jue Bang, Manish A Shah
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res
2023 ;29 (19) :3882 -3891
-
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, Sangwoo Kim, Hye Ryun Kim, Hwan Jung Yun, KCSG TRIUMPH Investigators
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
J Clin Oncol
2023 ;42 (5) :507 -517
-
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J Monk, Danny Nguyen, Do-Youn Oh, Alicia Okines, David M O'Malley, Paula Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cedric Van Marcke, Evan Y Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas E Stinchcombe, Tanios Bekaii-Saab
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
J Clin Oncol
2023 ;41 (36) :5569 -5578
-
Kohei Shitara, Sun Young Rha, Lucjan S Wyrwicz, Takashi Oshima, Nina Karaseva, Mikhail Osipov, Hisateru Yasui, Hiroshi Yabusaki, Sergey Afanasyev, Young-Kyu Park, Salah-Eddin Al-Batran, Takaki Yoshikawa, Patricio Yanez, Maria Dib Bartolomeo, Sara Lonardi, Josep Tabernero, Eric Van Cutsem, Yelena Y Janjigian, Do-Youn Oh, Jianming Xu, Xiao Fang, Chie-Schin Shih, Pooja Bhagia, Yung-Jue Bang, KEYNOTE-585 investigators
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Lancet Oncol
2023 ;25 (2) :212 -224
-
Hyeong Ho Jo, Nayoung Kim, Hyeon Jeong Oh, Du Hyun Song, Yonghoon Choi, Jaehyung Park, Jongchan Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hye Seung Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Soyeon Ahn
The Clinicopathological Features of Mixed Carcinoma in 7,215 Patients with Gastric Cancer in a Tertiary Hospital in South Korea.
Gut Liver
2022
-
Yonghoon Choi, Nayoung Kim, Ki Wook Kim, Hyeong Ho Jo, Jaehyung Park, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hyeon Jeong Oh, Hye Seung Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung-Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim
Sex-based differences in histology, staging, and prognosis among 2983 gastric cancer surgery patients.
World J Gastroenterol
2022 ;28 (9) :933 -947
-
Ji Yun Lee, Ju-Hyun Lee, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee, Soo-Mee Bang
Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Thromb Res
2022 ;213 :114 -118
-
Hye Sook Han, Kyoung Eun Lee, Young Ju Suh, Hee-Jung Jee, Bum Jun Kim, Hyeong Su Kim, Keun-Wook Lee, Min-Hee Ryu, Sun Kyung Baek, In Hae Park, Hee Kyung Ahn, Jae Ho Jeong, Min Hwan Kim, Dae Hyung Lee, Siheon Kim, Hyemi Moon, Serim Son, Ji-Hye Byun, Dong Sook Kim, Hyonggin An, Yeon Hee Park, Dae Young Zang
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group.
Ther Adv Med Oncol
2022 ;14 (0) :17588359221132628 -17588359221132628
-
Yu Jung Kim, Seok Joon Yoon, Sang-Yeon Suh, Yusuke Hiratsuka, Beodeul Kang, Si Won Lee, Hong-Yup Ahn, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee
Performance of clinician prediction of survival in oncology outpatients with advanced cancer.
PLoS One
2022 ;17 (4) :e0267467 -e0267467
-
Jin Hyun Park, Mi Young Kim, In Sil Choi, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Jin-Soo Kim
Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients.
PLoS One
2022 ;17 (10) :e0276497 -e0276497
-
Minsu Kang, Koung Jin Suh, Ji-Won Kim, Ja Min Byun, Jin Won Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang, Yu Jung Kim, Se Hyun Kim, Jee Hyun Kim, Jong Seok Lee, Keun-Wook Lee
Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study.
PLoS One
2022 ;17 (1) :e0261671 -e0261671
-
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, Do-Youn Oh, Diana L Hanna, Yoon-Koo Kang, Elena Elimova, Jorge Chaves, Rachel Goodwin, Jeeyun Lee, Lisle Nabell, Sun Young Rha, Jose Mayordomo, Anthony El-Khoueiry, Shubham Pant, Kanwal Raghav, Jin Won Kim, Amita Patnaik, Todd Gray, Rupert Davies, Mark A Ozog, Joseph Woolery, Keun-Wook Lee
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Lancet Oncol
2022 ;23 (12) :1558 -1570
-
Yoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik-Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen-Shi Chen, Li-Yuan Bai, Sung-Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
2022 ;23 (2) :234 -247
-
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Christophe Borg, Erika Hitre, Adrian A Udrea, Giovanni Gerardo Cardellino, Raquel Guardeno Sanchez, Helen Collins, Siddhartha Mitra, Yingsi Yang, Daniel V T Catenacci, Keun-Wook Lee
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Lancet Oncol
2022 ;23 (11) :1430 -1440
-
Eun Joo Kang, Yun-Gyoo Lee, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Jii Bum Lee, Jung Hye Kwon, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).
Korean J Intern Med
2022 ;37 (1) :190 -200
-
Eun Hee Jung, Si Won Lee, Yu Jung Kim, Beodeul Kang, Koung Jin Suh, Ju Hyun Lee, Esther Jeon, Dahee Kim, Sung Soun Hur, Ji Yun Lee, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Eduardo Bruera
Clinical Outcomes of Operating an Acute Palliative Care Unit at a Comprehensive Cancer Center.
JCO Oncol Pract
2022 ;18 (10) :e1661 -e1671
-
Bum Jun Kim, Hee-Jung Jee, Sun Young Rha, Hye Sook Han, Min-Hee Ryu, Se Hoon Park, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Gastric Cancer
2022 ;25 (3) :609 -618
-
Yoon-Koo Kang, Satoshi Morita, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Hiroki Sameshima, Li-Tzong Chen, Narikazu Boku
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Gastric Cancer
2022 ;25 (1) :207 -217
-
D V T Catenacci, Y-K Kang, H H Yoon, B Y Shim, S T Kim, D-Y Oh, A I Spira, S V Ulahannan, E J Avery, P M Boland, J Chao, H C Chung, F Gardner, S J Klempner, K-W Lee, S C Oh, J Peguero, M B Sonbol, L Shen, M Moehler, J Sun, D Li, M K Rosales, H Park
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
ESMO Open
2022 ;7 (5) :100563 -100563
-
Minsu Kang, Hee Young Na, Soomin Ahn, Ji-Won Kim, Sejoon Lee, Soyeon Ahn, Ju Hyun Lee, Jeonghwan Youk, Haesook T Kim, Kui-Jin Kim, Koung Jin Suh, Jun Suh Lee, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Yoo-Seok Yoon, Jee Hyun Kim, Jin-Haeng Chung, Ho-Seong Han, Jong Seok Lee
Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors.
Elife
2022 ;11
-
Manish A Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M Brooks, Bo Xu, Wei Li, Chiang J Li, Laura Borodyansky, Eric Van Cutsem
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res
2022 ;28 (17) :OF1 -OF9
-
Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, Charles S Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R Castro, Joseph Chao, Zev A Wainberg, Z Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Razvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Clin Cancer Res
2022 ;28 (16) :3489 -3498
-
Hyun Ae Jung, Keon-Uk Park, Sanghee Cho, Jinyeong Lim, Keun-Wook Lee, Min Hee Hong, Tak Yun, Ho Jung An, Woong-Yang Park, Sergio Pereira, Chan-Young Ock, Bhumsuk Keam
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Clin Cancer Res
2022 ;28 (19) :4240 -4247
-
Jwa Hoon Kim, Changhoon Yoo, Seyoung Seo, Jae Ho Jeong, Baek-Yeol Ryoo, Kyu-Pyo Kim, Jung Bok Lee, Keun-Wook Lee, Ji-Won Kim, Il-Hwan Kim, Myoungjoo Kang, Hyewon Ryu, Jaekyung Cheon, Sook Ryun Park
A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY.
Cancers (Basel)
2022 ;14 (3)
-
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
Cancer Res Treat
2022 ;54 (1) :109 -117
-
Yu Jung Kim, Yusuke Hiratsuka, Sang-Yeon Suh, Beodeul Kang, Si Won Lee, Hong-Yup Ahn, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee
A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients.
Cancer Res Treat
2022 ;54 (2) :621 -629
-
Jung Rae Cho, Keun-Wook Lee, Heung-Kwon Oh, Jin Won Kim, Ji-Won Kim, Duck-Woo Kim, Jee Hyun Kim, Sung-Bum Kang
Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer.
Ann Surg Treat Res
2022 ;102 (5) :271 -280
-
So Hyun Kang, Sa-Hong Min, Jin Won Kim, Eunju Lee, Sang Woo Park, Sangjun Lee, Hyeon Jeong Oh, Young Suk Park, Yoon Jin Lee, Ji-Won Kim, Sang-Hoon Ahn, Yun-Suhk Suh, Keun-Wook Lee, Hye Seung Lee, Hyung-Ho Kim
Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Ann Surg Oncol
2022 ;29 (8) :5084 -5091
-
Yusuke Hiratsuka, Yu Jung Kim, Sang-Yeon Suh, Seon Hye Won, Sung Eun Choi, Thomas W LeBlanc, Beodeul Kang, Si Won Lee, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee
The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer.
Ann Palliat Med
2022 ;11 (7) :2338 -2348
-
Yu Jung Kim, Yusuke Hiratsuka, Sang-Yeon Suh, Seon-Hye Won, Eun Hee Jung, Beodeul Kang, Si Won Lee, Hong-Yup Ahn, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee
Performance of mid-upper arm circumference and other prognostic indices based on inflammation and nutrition in oncology outpatients: a tertiary cancer center study.
Ann Palliat Med
2022 ;11 (10) :3171 -3180
-
Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang, SOPP study investigators
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
Gastric Cancer
2021 ;24 (1) :156 -167
-
Ji Yun Lee, Jin Ho Paik, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee, Jeong-Ok Lee
R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience.
Blood Res
2021 ;56 (4) :285 -292
-
Sung-Bum Kang, Jung Rae Cho, Seung-Yong Jeong, Jae Hwan Oh, Soyeon Ahn, Sunkyu Choi, Duck-Woo Kim, Bong Hwa Lee, Eui Gon Youk, Sung Chan Park, Seung Chul Heo, Doo-Seok Lee, Seung-Bum Ryoo, Ji Won Park, Hyoung-Chul Park, Sung-Min Lee, Sung Il Kang, Min Hyun Kim, Heung-Kwon Oh, Rumi Shin, Min Jung Kim, Kyoung Ho Lee, Young-Hoon Kim, Jae-Sung Kim, Keun-Wook Lee, Hye Seung Lee, Hyun Jung Kim, Young Soo Park, Dae Kyung Sohn, Kyu Joo Park, Seoul Colorectal Research Group (SECOG)
Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): A long-term prospective, multicentre, cohort study.
Lancet Reg Health West Pac
2021 ;6 :100087 -100087
-
Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy.
J Geriatr Oncol
2021 ;12 (6) :922 -929
-
Yeong Hak Bang, Yong Sang Hong, Ji Sung Lee, Keun-Wook Lee, Hye Sook Han, Sun Young Kim, Ji-Won Kim, Hee Kyung Kim, Jin Won Kim, Choi Ki Eun, Tae Won Kim, Jeong Eun Kim
Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
Clin Colorectal Cancer
2021 ;20 (2) :101 -112.e6
-
Yun-Gyoo Lee, Hyun Chang, Bhumsuk Keam, Sang Hoon Chun, Jihyun Park, Keon Uk Park, Seong Hoon Shin, Ho Jung An, Kyoung Eun Lee, Keun-Wook Lee, Hye Ryun Kim, Sung-Bae Kim, Myung-Ju Ahn, In Gyu Hwang
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Cancer Res Treat
2021 ;53 (3) :671 -677
-
Koung Jin Suh, Jin Won Kim, Ji Eun Kim, Ji Hea Sung, Jiwon Koh, Kui-Jin Kim, Ji-Won Kim, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee, Keun-Wook Lee
Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined using methylation analyses and its prognostic significance in resected gastric cancer.
PLoS One
2021 ;16 (6) :e0252480 -e0252480
-
Sang-A Kim, Hyejoo Park, Kui-Jin Kim, Ji-Won Kim, Ji Hea Sung, Milang Nam, Ju Hyun Lee, Eun Hee Jung, Koung Jin Suh, Ji Yun Lee, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.
Sci Rep
2021 ;11 (1) :23803 -23803
-
Ji Yun Lee, Minsu Kang, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee, Jeong-Ok Lee
Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Mycoses
2021 ;64 (1) :60 -65
-
Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Taihei Nishiyama, Li-Tzong Chen, Yoon-Koo Kang
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Gastric Cancer
2021 ;24 (4) :946 -958
-
Ki Wook Kim, Nayoung Kim, Yonghoon Choi, Won Seok Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Young Suk Park, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim
Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study.
Gastric Cancer
2021 ;24 (4) :844 -857
-
Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, Min-Hee Ryu, Se Hoon Park, Sun Young Rha, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, In-Ho Kim, Sun Jin Sym, So Yeon Oh, Hyeong Su Kim, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Ther Adv Med Oncol
2021 ;13 (0) :17588359211042812 -17588359211042812
-
Bum-Sup Jang, Yu Jin Lim, Changhoon Song, Seung Hyuck Jeon, Keun-Wook Lee, Sung-Bum Kang, Yoon Jin Lee, Jae-Sung Kim
Image-based deep learning model for predicting pathological response in rectal cancer using post-chemoradiotherapy magnetic resonance imaging.
Radiother Oncol
2021 ;161 :183 -190
-
Eun Joo Kang, Myung-Ju Ahn, Chan-Young Ock, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Byung-Ho Nam, Sung-Bae Kim, Bhumsuk Keam
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.
Clin Cancer Res
2021 ;27 (19) :5272 -5279
-
Joel Guigay, Keun-Wook Lee, Manish R Patel, Amaury Daste, Deborah J Wong, Sanjay Goel, Michael S Gordon, Martin Gutierrez, Ani Balmanoukian, Christophe Le Tourneau, Alain Mita, Damien Vansteene, Ulrich Keilholz, Patrick Schoffski, Hans Juergen Grote, Dongli Zhou, Marcis Bajars, Nicolas Penel
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
J Immunother Cancer
2021 ;9 (10)
-
Nehal J Lakhani, Laura Q M Chow, Justin F Gainor, Patricia LoRusso, Keun-Wook Lee, Hyun Cheol Chung, Jeeyun Lee, Yung-Jue Bang, Frank Stephen Hodi, Won Seog Kim, Rafael Santana-Davila, Philip Fanning, Pierre Squifflet, Feng Jin, Tracy C Kuo, Hong I Wan, Jaume Pons, Sophia S Randolph, Wells A Messersmith
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
2021 ;22 (12) :1740 -1751
-
Tae Kyu Chung, Hyun A Lee, Sang-In Park, Do-Youn Oh, Keun-Wook Lee, Jin Won Kim, Jee Hyun Kim, Ahmi Woo, Su Jin Lee, Yung-Jue Bang, Howard Lee
A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Clin Transl Sci
2021 ;14 (3) :990 -1001
-
ApoloAndrea B, EllertonJohn A, InfanteJeffrey R, AgrawalManish, GordonMichael S, AljumailyRaid, GourdinTheodore, DirixLuc, LeeKeun-Wook, TaylorMatthew H, SchoffskiPatrick, WangDing, RavaudAlain, ManitzJuliane, PennockGregory, RuisiMary, GulleyJames L, PatelManish R
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
J Immunother Cancer
2020 ;8 (2)
-
KimJin Won, ChoSung-Yup, ChaeJeesoo, KimJi-Won, KimTae-Yong, LeeKeun-Wook, OhDo-Youn, BangYung-Jue, ImSeock-Ah
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Cancer Res Treat
2020 ;52 (4) :1178 -1187
-
ChunYou Jin, KimSeong-Geun, LeeKeun-Wook, ChoSang Hee, KimTae Won, BaekJi Yeon, ParkYoung Suk, HongSoojung, ChuChong Woo, BeomSeung-Hoon, JungMinkyu, ShinSang Joon, AhnJoong Bae
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Clin Colorectal Cancer
2020 ;19 (3) :e140 -e150
-
Jwa Hoon Kim, Sun Young Kim, Ji Yeon Baek, Yong Jun Cha, Joong Bae Ahn, Han Sang Kim, Keun-Wook Lee, Ji-Won Kim, Tae-You Kim, Won Jin Chang, Joon Oh Park, Jihun Kim, Jeong Eun Kim, Yong Sang Hong, Yeul Hong Kim, Tae Won Kim
A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Cancer Res Treat
2020 ;52 (4) :1135 -1144
-
ChenLi-Tzong, SatohTaroh, RyuMin-Hee, ChaoYee, KatoKen, ChungHyun Cheol, ChenJen-Shi, MuroKei, KangWon Ki, YehKun-Huei, YoshikawaTakaki, OhSang Cheul, BaiLi-Yuan, TamuraTakao, LeeKeun-Wook, HamamotoYasuo, KimJong Gwang, ChinKeisho, OhDo-Youn, MinashiKeiko, ChoJae Yong, TsudaMasahiro, SameshimaHiroki, KangYoon-Koo, BokuNarikazu
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Gastric Cancer
2020 ;23 (3) :510 -519
-
LEE KEUN WOOK, Chung Tae Kyu, Lee Howard, Lee Hyun A, Park Sang-In, Oh Do-Youn, Kim Jin Won, Kim Jee Hyun, Woo Ahmi, Lee Su Jin, Bang Yung-Jue
A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors
CTS-CLIN TRANSL SCI
2020 ;14 (3) :990 -1001
-
Hyun Jung Lee, Kui-Jin Kim, Ji Hea Sung, Milang Nam, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells.
Cancers (Basel)
2020 ;12 (9)
-
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo Raul Castro, Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Christian Caglevic, Luis Villanueva, Eray Goekkurt, Hironaga Satake, Peter Enzinger, Maria Alsina, Al Benson, Joseph Chao, Andrew H Ko, Zev A Wainberg, Uma Kher, Sukrut Shah, S Peter Kang, Josep Tabernero
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
JAMA Oncol
2020 ;6 (10) :1571 -1580
-
Seung Hyuck Jeon, Changhoon Song, Eui Kyu Chie, Bohyoung Kim, Young Hoon Kim, Won Chang, Yoon Jin Lee, Joo-Hyun Chung, Jin Beom Chung, Keun-Wook Lee, Sung-Bum Kang, Jae-Sung Kim
Combining Radiomics and Blood Test Biomarkers to Predict the Response of Locally Advanced Rectal Cancer to Chemoradiation.
In Vivo
2020 ;34 (5) :2955 -2965
-
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
BMC Cancer
2020 ;20 (1) :813 -813
-
Kui-Jin Kim, Ji-Won Kim, Ji Hea Sung, Koung Jin Suh, Ji Yun Lee, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Hark Kyun Kim, Keun-Wook Lee
PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Sci Rep
2020 ;10 (1) :12308 -12308
-
Yoon-Koo Kang, Keisho Chin, Hyun Cheol Chung, Shigenori Kadowaki, Sang Cheul Oh, Norisuke Nakayama, Keun-Wook Lee, Hiroki Hara, Ik-Joo Chung, Masahiro Tsuda, Se Hoon Park, Hisashi Hosaka, Shuichi Hironaka, Yoshinori Miyata, Min-Hee Ryu, Hideo Baba, Ichinosuke Hyodo, Yung-Jue Bang, Narikazu Boku
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Lancet Oncol
2020 ;21 (8) :1045 -1056
-
Ji Hyun Park, Sang Hoon Chun, Yun-Gyoo Lee, Hyun Chang, Keun-Wook Lee, Hye Ryun Kim, Seong Hoon Shin, Ho Jung An, Kyoung Eun Lee, In Gyu Hwang, Myung-Ju Ahn, Sung-Bae Kim, Bhumsuk Keam
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
J Cancer Res Clin Oncol
2020 ;146 (12) :3359 -3369
-
Daniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E Uronis, Keun-Wook Lee, Matthew C H Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy, Howard S Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A Marrone, Ronan J Kelly, Rosalyn A Juergens, Jong Gwang Kim, Johanna C Bendell, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, A Craig Lockhart, Keith L Knutson, Jennifer Yen, Aleksandra Franovic, Jeffrey L Nordstrom, Daner Li, Jon Wigginton, Jan K Davidson-Moncada, Minori Koshiji Rosales, Yung-Jue Bang, CP-MGAH22-5 Study Group
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
2020 ;21 (8) :1066 -1076
-
Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma.
Cancers (Basel)
2020 ;12 (7)
-
Joo Ho Lee, Byung-Hee Kang, Changhoon Song, Sung-Bum Kang, Hye Seung Lee, Keun-Wook Lee, Eui Kyu Chie, Jae-Sung Kim
Microsatellite Instability Correlated Inflammatory Markers and their Prognostic Value in the Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Hypothesis-generating Study.
In Vivo
2020 ;34 (4) :2119 -2126
-
Yonghoon Choi, Nayoung Kim, Chang Yong Yun, Yoon Jin Choi, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Sang-Hoon Ahn, Do Joong Park, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Dong Ho Lee, Hyung-Ho Kim
Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15?years.
Gastric Cancer
2020 ;23 (6) :1051 -1063
-
Sang-A Kim, Ji-Won Kim, Koung Jin Suh, Won Chang, Jin Won Kim, Heung-Kwon Oh, Jai Young Cho, Duck-Woo Kim, Sukki Cho, Jee Hyun Kim, Kwhanmien Kim, Sung-Bum Kang, Sanghoon Jheon, Keun-Wook Lee
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
J Cancer Res Clin Oncol
2020 ;146 (9) :2399 -2410
-
Byung-Hee Kang, Changhoon Song, Sung-Bum Kang, Keun-Wook Lee, Hye Seung Lee, Jae-Sung Kim
Nomogram for Predicting the Pathological Tumor Response from Pre-treatment Clinical Characteristics in Rectal Cancer.
Anticancer Res
2020 ;40 (4) :2171 -2177
-
Grace S Ahn, Hak Ro Kim, Beodeul Kang, Sung Soun Hur, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Yu Jung Kim
Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center.
Ann Palliat Med
2020 ;9 (2) :216 -223
-
Daniel V T Catenacci, Drew Rasco, Jeeyun Lee, Sun Young Rha, Keun-Wook Lee, Yung Jue Bang, Johanna Bendell, Peter Enzinger, Neyssa Marina, Hong Xiang, Wei Deng, Janine Powers, Zev A Wainberg
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
J Clin Oncol
2020 ;38 (21) :2418 -2426
-
Jin Won Kim, Ahrum Min, Seock-Ah Im, Hyemin Jang, Yu Jin Kim, Hee-Jun Kim, Kyung-Hun Lee, Tae-Yong Kim, Keun Wook Lee, Do-Youn Oh, Jee-Hyun Kim, Yung-Jue Bang
TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy.
Cancers (Basel)
2020 ;12 (2)
-
Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Cancer Res Treat
2020 ;52 (3) :661 -670
-
Ronan J Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V T Catenacci, Hyun Cheol Chung, Zev A Wainberg, Michael K Gibson, Keun-Wook Lee, Johanna C Bendell, Crystal S Denlinger, Cheng Ean Chee, Takeshi Omori, Rom Leidner, Heinz-Josef Lenz, Yee Chao, Marlon C Rebelatto, Philip Z Brohawn, Peng He, Jennifer McDevitt, Siddharth Sheth, Judson M Englert, Geoffrey Y Ku
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res
2020 ;26 (4) :846 -854
-
Taroh Satoh, Yoon-Koo Kang, Yee Chao, Min-Hee Ryu, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Mitsunobu Tanimoto, Li-Tzong Chen, Narikazu Boku
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Gastric Cancer
2020 ;23 (1) :143 -153
-
Jang Yeonji, Kim Namju, Lee Keun Wook, Choung Ho Kyung, Khwarg Sang In
Nasolacrimal Duct Stenosis after Oral Capecitabine Administration
KOREAN J OPHTHALMOL
2019 ;33 (1) :95 -96
-
Choe Hun Jee, Kim Jin Won, Lee Hye Seung, Lee Keun-Wook, Han Song-Hee, Lee Ju Hyun, Ahn Sang-Hoon, Park Do Joong, Kim Ji-Won, Kim Yu Jung, Kim Jee Hyun, Kim Hyung-Ho
Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker
CANCERS
2019 ;12 (1)
-
Kwon Ji-Hyun, Lee Jong Seok, Kim Kui-Jin, Sung Ji Hea, Suh Koung Jin, Lee Ji Yun, Kim Ji-Won, Kim Se Hyun, Lee Jeong-Ok, Kim Jin Won, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Bang Soo-Mee, Kim Soyeon, Yoon Sung-Soo
Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
CELLS-BASEL
2019 ;8 (12)
-
Koh Jiwon, Lee Ho-Young, Lee Hye Seung, Nam Soo Kyung, Lee Youn Woo, Kim Jin Won, Lee Keun-Wook, Ock Chan-Young, Oh Do-Youn, Ahn Sang-Hoon, Kim Hyung-Ho, Kang Keon-Wook, Kim Woo Ho
Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients
BIOMOLECULES
2019 ;9 (12)
-
Choi Yeonjoo, Kim Jin Won, Suh Koung Jin, Lim Yoo-Joo, Lee Ji Yun, Kang Beo-Deul, Kim Ji-Won, Kim Se-Hyun, Lee Jeong-Ok, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Bang Soo-Mee, Lee Jong Seok
Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards
BMC PALLIAT CARE
2019 ;18 (1)
-
Hong Yong Sang, Kim Tae Won, Kim Sun Young, Lee Ji Sung, Nam Byung-Ho, Kim Kyu-Pyo, Kim Jeong Eun, Park Young Suk, Park Joon Oh, Baek Ji Yeon, Kim Tae-You, Lee Keun-Wook, Ahn Joong Bae, Lim Seok-Byung, Yu Chang Sik, Kim Jin Cheon, Yun Seong Hyeon, Kim Jong Hoon, Park Jin-Hong, Park Hee Chul, Jung Kyung Hae
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial
J CLIN ONCOL
2019 ;37 (33) :3111 -3123
-
Koh Jiwon, Lee Hye Seung, Lee Keun-Wook, Nam Soo Kyung, Seo An Na, Kim Ji-Won, Kim Jin Won, Park Do Joong, Kim Hyung-Ho, Kim Woo Ho
Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications
ONCOLOGIST
2019 ;24 (12) :e1321 -e1330
-
Choe Hun Jee, Lee Ji Yun, Suh Koung Jin, Kim Minyoung, Kim Man Jin, Park Sung Sup, Kim Ji-Won, Kim Se Hyun, Kim Jin Won, Lee Jeong-Ok, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Bang Soo-Mee, Lee Jong Seok
Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea: A case report
MEDICINE
2019 ;98 (28)
-
Han Song-Hee, Shin Eun, Kim Jin Won, Kim Milim, Kim Jee Hyun, Lee Keun-Wook, Kim Bo-Hyung, Oh Heung-Kwon, Kim Duck-Woo, Kang Sung-Bum, Kim Hyunchul
Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
ONCOL LETT
2019 ;17 (6) :5572 -5580
-
Oh Do-Youn, Lee Keun-Wook, Han Sae-Won, Kim Jin Won, Shin Jung-Won, Jo Seong-Jin, Won Jonghwa, Hahn Seokyung, Lee Howard, Kim Woo Ho, Bang Yung-Jue
A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
ONCOLOGIST
2019 ;24 (8) :1037 -e636
-
Yoo Shin Hye, Keam Bhumsuk, Ock Chan-Young, Kim Sehui, Han Buhm, Kim Ji-Won, Lee Keun-Wook, Jeon Yoon Kyung, Jung Kyeong Cheon, Chung Eun-Jae, Kwon Seong Keun, Ahn Soon-Hyun, Sung Myung-Whun, Heo Dae Seog
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
SCI REP-UK
2019 ;9 (1)
-
Bang Yung-Jue, Kim Tae-Yong, Han Hye Sook, Lee Keun-Wook, Zang Dae Young, Rha Sun Young, Park Young Iee, Kim Jin-Soo, Lee Kyung-Hun, Park Se Hoon, Song Eun-Kee, Jung Soo-A, Lee NaMi, Kim Yeul Hong, Cho Jae Yong
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
GASTRIC CANCER
2019 ;22 (6) :1206 -1214
-
Jeon Seung Hyuck, Song Changhoon, Chie Eui Kyu, Kim Bohyoung, Kim Young Hoon, Chang Won, Lee Yoon Jin, Chung Joo-Hyun, Chung Jin Beom, Lee Keun-Wook, Kang Sung-Bum, Kim Jae-Sung
Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer
RADIAT ONCOL
2019 ;14 (1)
-
Han Jae Joon, Kim Jin Won, Suh Koung Jin, Kim Ji-Won, Kim Se Hyun, Kim Yu Jung, Kim Jee Hyun, Lee Jong Seok, Lee Keun-Wook
Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer
ASIA-PAC J CLIN ONCO
2019 ;15 (3) :158 -165
-
Keam Bhumsuk, Lee Keun-Wook, Lee Se-Hoon, Kim Jin-Soo, Kim Jin Ho, Wu Hong-Gyun, Eom Keun-Yong, Kim Suzy, Ahn Soon-Hyun, Chung Eun-Jae, Kwon Seong Keun, Jeong Woo-Jin, Jung Young Ho, Kim Ji-Won, Heo Dae Seog
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
ONCOLOGIST
2019 ;24 (6) :751 -e231
-
Chung Eun-Jae, Ahn Soon-Hyun, Rho Young-Soo, Jeong Woo-Jin, Jung Young Ho, Kwon Seong Keun, Kwon Tack-Kyun, Sung Myung-Whun, Keam Bhumsuk, Heo Dae-Seog, Kim Jin Ho, Wu Hong-Gyun, Lee Keun-Wook, Eom Keun-Yong
Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases
ORAL ONCOL
2019 ;89 :84 -94
-
Chung Hyun Cheol, Arkenau Hendrik-Tobias, Lee Jeeyun, Rha Sun Young, Oh Do-Youn, Wyrwicz Lucjan, Kang Yoon-Koo, Lee Keun-Wook, Infante Jeffrey R, Lee Sung Sook, Kemeny Margaret, Keilholz Ulrich, Melichar Bohuslav, Mita Alain, Plummer Ruth, Smith Denis, Gelb Arnold B, Xiong Huiling, Hong Janet, Chand Vikram, Safran Howard
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
J IMMUNOTHER CANCER
2019 ;7 (1)
-
Keilholz Ulrich, Mehnert Janice M, Bauer Sebastian, Bourgeois Hugues, Patel Manish R, Gravenor Donald, Nemunaitis John J, Taylor Matthew H, Wyrwicz Lucjan, Lee Keun-Wook, Kasturi Vijay, Chin Kevin, von Heydebreck Anja, Gulley James L
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
J IMMUNOTHER CANCER
2019 ;7 (1)
-
Kim Jin Won, Kim Jong Gwang, Kang Byung Woog, Chung Ik-Joo, Hong Young Seon, Kim Tae-You, Song Hong Suk, Lee Kyung Hee, Zang Dae Young, Ko Yoon Ho, Song Eun-Kee, Baek Jin Ho, Koo Dong-Hoe, Oh So Yeon, Cho Hana, Lee Keun-Wook
Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
CANCER RES TREAT
2019 ;51 (1) :223 -239
-
Kang Y-K, Boku N, Ryu M-H, Kato K, Chung H C, Minashi K, Lee K-W, Cho H, Kang W K, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen L-T
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
ANN ONCOL
2019 ;30 (2) :250 -258
-
Shin Junghoon, Kim Se Hyun, Chung Jin-Haeng, Lee Kyu Sang, Suh Koung Jin, Lee Ji Yun, Kim Ji-Won, Lee Jeong-Ok, Kim Jin-Won, Kim Yu-Jung, Lee Keun-Wook, Kim Jee Hyun, Bang Soo-Mee, Lee Jong-Seok
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
CANCER RES TREAT
2019 ;51 (3) :1086 -1097
-
Lee Jeong-Ok, Bang Soo-Mee, Lee Ji Yun, Chun Eun Ju, Choi Sang Il, Kim Jin Won, Kim Se Hyun, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Lee Jong Seok
Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study
SUPPORT CARE CANCER
2019 ;27 (7) :2507 -2515
-
Moehler Markus, Ryu Min-Hee, Dvorkin Mikhail, Lee Keun-Wook, Co?kun Hasan ?, Wong Rachel, Chung Hyun C, Poltoratsky Artem, Tsuji Akihito, Yen Chia Jui, Muntean Alina S, Le Sourd Samuel, Vaccaro Gina M, Overton Lindsay, Boku Narikazu, Wainberg Zev A, Patel Manish, Sharma Maitreyi, Xiong Huiling, Conti Ilaria, Taieb Julien, Bang Yung-Jue
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
FUTURE ONCOL
2019 ;15 (6) :567 -577
-
Lee Keun-Wook, Cho Jae Yong, Maeng Chi Hoon, Kim Tae-You, Zang Dae Young, Kim Yeul Hong, Hwang In Gyu, Oh Sang Cheul, Chung Joo Seop, Song Hong Suk, Kim Jin Won, Jeong Su Jin
A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)
ONCOLOGIST
2019 ;24 (1) :18 -e24
-
Son I T, Lee H S, Ihn M H, Lee K H, Kim D-W, Lee K-W, Kim J-S, Kang S-B
Isolation of internal and external sphincter progenitor cells from the human anal sphincter with or without radiotherapy
COLORECTAL DIS
2019 ;21 (1) :38 -47
-
Yhim Ho-Young, Bang Soo-Mee, Choi Won-Il, Kim Sung-Hyun, Nam Seung-Hyun, Kim Kyoung Ha, Mun Yeung-Chul, Oh Doyeun, Hwang Hun-Gyu, Lee Keun-Wook, Song Eun-Kee, Kwon Yong Shik
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
KOREAN J INTERN MED
2019 ;34 (5) :1125 -1135
-
Lim Sun Min, Yun Hwan Jung, Cho Sang Hee, Hwang In Gyu, Choi Jae Woo, Chang Hyun, Ahn Myung-Ju, Park Keon Uk, Kim Ji-Won, Ko Yoon Ho, Ahn Hee Kyung, Cho Byoung Chul, Nam Byung-Ho, Chun Sang Hoon, Hong Ji Hyung, Kwon Jung Hye, Choi Jong Gwon, Kang Eun Joo, Yun Tak, Lee Keun-Wook, Kim Joo-Hang, Kim Jin Soo, Lee Hyun Woo, Kim Min Kyoung, Jung Dongmin, Kim Ji Eun, Keam Bhumsuk, Kim Sangwoo, Kim Hye Ryun
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
CANCER RES TREAT
2019 ;51 (1) :300 -312
-
Lee Yun-Gyoo, Kim Inho, Oh Somi, Shin Dong-Yeop, Koh Youngil, Lee Keun-Wook
Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia
KOREAN J INTERN MED
2019 ;34 (1) :178 -183
-
Lee Joo Ho, Song Changhoon, Kang Sung-Bum, Lee Hye Seung, Lee Keun-Wook, Kim Jae-Sung
Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
ANTICANCER RES
2018 ;38 (12) :6905 -6910
-
Choi In Sil, Kim Jee Hyun, Lee Ju Hyun, Suh Koung Jin, Lee Ji Yun, Kim Ji-Won, Kim Se-Hyun, Kim Jin Won, Lee Jeong-Ok, Kim Yu Jung, Bang Soo-Mee, Lee Jong Seok, Lee Keun-Wook
A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
PLOS ONE
2018 ;13 (10)
-
Kim Se Hyun, Ryu Haram, Ock Chan-Young, Suh Koung Jin, Lee Ji Yun, Kim Ji-Won, Lee Jeong-Ok, Kim Jin Won, Kim Yu Jung, Lee Keun-Wook, Bang Soo-Mee, Kim Jee Hyun, Lee Jong Seok, Ahn Joong Bae, Kim Kui-Jin, Rha Sun Young
BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
INT J MOL SCI
2018 ;19 (10)
-
Song Changhoon, Chung Joo-Hyun, Kang Sung-Bum, Kim Duck-Woo, Oh Heung-Kwon, Lee Hye Seung, Kim Jin Won, Lee Keun-Wook, Kim Jee Hyun, Kim Jae-Sung
Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System
CANCERS
2018 ;10 (9)
-
Yen Chia-Jui, Muro Kei, Kim Tae-Won, Kudo Masatoshi, Shih Jin-Yuan, Lee Keun-Wook, Chao Yee, Kim Sang-We, Yamazaki Kentaro, Sohn JooHyuk, Cheng Rebecca, Zhang Yawei, Binder Polina, Mi Gu, Orlando Mauro, Chung Hyun Cheol
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
J Glob Oncol
2018 ;4 :1 -12
-
Bang Y-J, Ruiz E Yanez, Van Cutsem E, Lee K-W, Wyrwicz L, Schenker M, Alsina M, Ryu M-H, Chung H-C, Evesque L, Al-Batran S-E, Park S H, Lichinitser M, Boku N, Moehler M H, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
ANN ONCOL
2018 ;29 (10) :2052 -2060
-
Kim Sun Young, Joo Jungnam, Kim Tae Won, Hong Yong Sang, Kim Jeong Eun, Hwang In Gyu, Kim Beom Gyu, Lee Keun-Wook, Kim Ji-Won, Oh Ho-Suk, Ahn Joong Bae, Zang Dae Young, Kim Dae Yong, Oh Jae Hwan, Baek Ji Yeon
A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03
INT J RADIAT ONCOL
2018 ;101 (4) :889 -899
-
Choi In Sil, Choi Mihong, Lee Ju Hyun, Kim Jee Hyun, Suh Koung Jin, Lee Ji Yun, Kang Beodeul, Kim Ji-Won, Kim Se-Hyun, Kim Jin Won, Lee Jeong-Ok, Kim Yu Jung, Bang Soo-Mee, Lee Jong Seok, Lee Keun-Wook
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
PLOS ONE
2018 ;13 (6)
-
Lee Yoontaek, Min Sa-Hong, Park Ki Bum, Park Young Suk, Kim Ji-Won, Ahn Sang-Hoon, Kim Jin Won, Park Do Joong, Lee Keun-Wook, Kim Hyung-Ho
Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis
J GASTRIC CANCER
2018 ;18 (1) :58 -68
-
Xu Rui-Hua, Muro Kei, Morita Satoshi, Iwasa Satoru, Han Sae Won, Wang Wei, Kotaka Masahito, Nakamura Masato, Ahn Joong Bae, Deng Yan-Hong, Kato Takeshi, Cho Sang-Hee, Ba Yi, Matsuoka Hiroshi, Lee Keun-Wook, Zhang Tao, Yamada Yasuhide, Sakamoto Junichi, Park Young Suk, Kim Tae Won
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
LANCET ONCOL
2018 ;19 (5) :660 -671
-
Jung Minkyu, Ryu Min-Hee, Oh Do Youn, Kang Myounghee, Zang Dae Young, Hwang In Gyu, Lee Keun-Wook, Kim Ki Hyang, Shim Byoung Yong, Song Eun Kee, Sym Sun Jin, Han Hye Sook, Park Young Lee, Kim Jin Soo, Lee Hyun Woo, Lee Moon Hee, Koo Dong-Hoe, Song Hong Suk, Lee Namsu, Yang Sung Hyun, Choi Dae Ro, Hong Young Seon, Lee Kyoung Eun, Maeng Chi Hoon, Baek Jin Ho, Kim Samyong, Kim Yeul Hong, Rha Sun Young, Cho Jae Yong, Kang Yoon-Koo
Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)
GASTRIC CANCER
2018 ;21 (5) :819 -830
-
Patel Manish R, Ellerton John, Infante Jeffrey R, Agrawal Manish, Gordon Michael, Aljumaily Raid, Britten Carolyn D, Dirix Luc, Lee Keun-Wook, Taylor Mathew, Schoffski Patrick, Wang Ding, Ravaud Alain, Gelb Arnold B, Xiong Junyuan, Rosen Galit, Gulley James L, Apolo Andrea B
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
LANCET ONCOL
2018 ;19 (1) :51 -64
-
Lee Keun-Wook, Lee Dae Ho, Kang Jin Hyoung, Park Joon Oh, Kim Se Hyun, Hong Yong Sang, Kim Seung Tae, Oh Do-Youn, Bang Yung-Jue
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
ONCOLOGIST
2018 ;23 (2) :155 -e17
-
Kim Tae Min, Lee Keun-Wook, Oh Do-Youn, Lee Jong-Seok, Im Seock-Ah, Kim Dong-Wan, Han Sae-Won, Kim Yu Jung, Kim Tae-You, Kim Jee Hyun, Han Hyesun, Kim Woo Ho, Bang Yung-Jue
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
CANCER RES TREAT
2018 ;50 (3) :835 -842
-
Kim Namju, Kim Jin Won, Baek Je-Hyun, Kim Jin-Soo, Choung Ho-Kyung, Kim Tae-Yong, Lee Kyung-Hun, Bang Yung-Jue, Khwarg Sang In, Ahn Sang-Hoon, Park Do Joong, Kim Hyung-Ho, Chung Jae-Yong, Ahn Soyeon, Lee Keun-Wook
S-1-Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study
CANCER RES TREAT
2018 ;50 (1) :30 -39
-
Choi In Sil, Lee Keun-Wook, Zang Dae Young, Ryu Min-Hee, Kim Ki Hyang, Kim Mi-Jung, Han Hye Sook, Koh Sung Ae, Park Jin Hyun, Kim Jin Won, Nam Byung-Ho
Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial
Contemp Clin Trials Commun
2017 ;8 :55 -61
-
Kim Ji-Won, Lee Hye Seung, Nam Kyung Han, Ahn Soyeon, Kim Jin Won, Ahn Sang-Hoon, Park Do Joong, Kim Hyung-Ho, Lee Keun-Wook
PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer
Oncotarget
2017 ;8 (53) :90948 -90958
-
Bang Yung-Jue, Boku Narikazu, Chin Keisho, Hodgson Darren, Im Seock-Ah, Lee Keun-Wook, Liu Yu-Zhen, Locker Gershon, Park Se Hoon, Qin Shukui, Rha Sun Young, Rowe Phil, Shen Lin, Shi Xiaojin, Xu Nong, Xu Rui-Hua
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
LANCET ONCOL
2017 ;18 (12) :1637 -1651
-
Ock Chan-Young, Jang Hee-Jin, Hwang Jun-Eul, Keam Bhumsuk, Kim Sang-Bae, Shim Jae-Jun, Park Sarang, Sohn Bo Hwa, Cha Minse, Ajani Jaffer A, Kopetz Scott, Lee Keun-Wook, Kim Tae Min, Heo Dae Seog, Lee Ju-Seog
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
NAT COMMUN
2017 ;8 (1)
-
Kim Se Hyun, Kim Mi-Jung, Lee Jong Seok, Kim Yu Jung, Chang Hyun, Kim Jin Won, Lee Jeong-Ok, Lee Keun-Wook, Kim Jee Hyun, Bang Soo-Mee
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
MEDICINE
2017 ;96 (42)
-
Kang Yoon-Koo, Boku Narikazu, Satoh Taroh, Ryu Min-Hee, Chao Yee, Kato Ken, Chung Hyun Cheol, Chen Jen-Shi, Muro Kei, Kang Won Ki, Yeh Kun-Huei, Yoshikawa Takaki, Oh Sang Cheul, Bai Li-Yuan, Tamura Takao, Lee Keun-Wook, Hamamoto Yasuo, Kim Jong Gwang, Chin Keisho, Oh Do-Youn, Minashi Keiko, Cho Jae Yong, Tsuda Masahiro, Chen Li-Tzong
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
LANCET
2017 ;390 (10111) :2461 -2471
-
Suh Koung Jin, Sung Ji Hea, Kim Jin Won, Han Song-Hee, Lee Hye Seung, Min Ahrum, Kang Mi Hyun, Kim Ji Eun, Kim Ji-Won, Kim Se Hyun, Lee Jeong-Ok, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Bang Soo-Mee, Im Seock-Ah, Lee Jong Seok
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
Oncotarget
2017 ;8 (38) :63901 -63910
-
Kim Jin Won, Kim Haeryoung, Park Sehhoon, Kim Ji-Won, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Kim Jai Hwan, Hwang Jin-Hyeok, Choi Young Rok, Cho Jai Young, Yoon Yoo-Seok, Han Ho-Seong
Prognostic value of p21-activated kinase 4 in resected pancreatic cancer
APMIS
2017 ;125 (8) :699 -707
-
Lee Ji Yun, Bang Soo-Mee, Lee Ju-Hyun, Lee Heeyoung, Kang Beodeul, Kim Ji-Won, Kim Se Hyun, Lee Jeong-Ok, Kim Jin Won, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Choi Hyoung Soo, Lee Jong Seok
Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea
THROMB RES
2017 ;155 :86 -91
-
Son Il Tae, Kim Young Hoon, Lee Kyoung Ho, Kang Sung Il, Kim Duck-Woo, Shin Eun, Lee Keun-Wook, Ahn Soyeon, Kim Jae-Sung, Kang Sung-Bum
Oncologic relevance of magnetic resonance imaging-detected threatened mesorectal fascia for patients with mid or low rectal cancer: A longitudinal analysis before and after long-course, concurrent chemoradiotherapy
SURGERY
2017 ;162 (1) :152 -163
-
Kim Ji-Won, Lee Keun-Wook, Kim Kyu-Pyo, Lee Ju Hyun, Hong Yong Sang, Kim Jeong-Eun, Kim Sun Young, Park Sook Ryun, Nam Byung-Ho, Cho Sang-Hee, Chung Ik-Joo, Park Young Suk, Oh Ho-Suk, Lee Myung-Ah, Kang Hye Jin, Park Young Iee, Song Eun-Kee, Han Hye Sook, Lee Kyu Taeg, Shin Dong Bok, Kang Jung Hun, Zang Dae Young, Kim Jee Hyun, Kim Tae Won
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer
ONCOLOGIST
2017 ;22 (3) :293 -303
-
Yoo Shin Hye, Kim Se Hyun, Kim Hyean-Ji, Kim Jeong-Han, Lee Gyeong-Won, Lee Jeong Hee, Kim Ji-Won, Kim Jin Won, Lee Jeong-Ok, Kim Yu Jung, Lee Keun-Wook, Kim Jee Hyun, Bang Soo-Mee, Lee Jong Seok
Nephrotic syndrome associated with metastatic thymoma treated with chemotherapy
MEDICINE
2017 ;96 (1)
-
Lee Keun-Wook, Kim Bum Jun, Kim Mi-Jung, Han Hye Sook, Kim Jin Won, Park Young Iee, Park Sook Ryun
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
CANCER RES TREAT
2017 ;49 (3) :706 -716
-
Choi Yeonjoo, Kim Jin Won, Nam Kyung Han, Han Song-Hee, Kim Ji-Won, Ahn Sang-Hoon, Park Do Joong, Lee Keun-Wook, Lee Hye Seung, Kim Hyung-Ho
Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer
GASTRIC CANCER
2017 ;20 (4) :602 -611
-
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
CHIN J CANCER
2016 ;35 (1)
-
Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer-a real-world outcome study
JPN J CLIN ONCOL
2016 ;46 (12) :1108 -1117
-
Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
CLIN CANCER RES
2016 ;22 (24) :6228 -6235
-
Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population
CL LYMPH MYELOM LEUK
2016 ;16 (9) :503 -510.e3
-
Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer
J CANCER RES CLIN
2016 ;142 (3) :687 -697
-
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer
J GASTROEN HEPATOL
2016 ;31 (3) :581 -589
-
Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
GASTRIC CANCER
2016 ;19 (1) :42 -52
-
Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer
CANCER RES TREAT
2016 ;48 (3) :978 -989
-
Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
GASTRIC CANCER
2016 ;19 (4) :1095 -1103
-
Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment (18)FFDG PET/CT scans in locally advanced rectal cancer
EUR J NUCL MED MOL I
2016 ;43 (3) :422 -431
-
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells
CANCER RES TREAT
2016 ;48 (1) :355 -364
-
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
CANCER RES TREAT
2016 ;48 (1) :28 -36
-
Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment
ANTICANCER RES
2015 ;35 (10) :5631 -5638
-
A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7
PLOS ONE
2015 ;10 (9)
-
Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy
PLOS ONE
2015 ;10 (9)
-
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer
ONCOLOGIST
2015 ;20 (10) :1119 -1120
-
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
J CLIN ONCOL
2015 ;33 (33) :3858 -3865
-
Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer
ONCOLOGIST
2015 ;20 (8) :896 -897
-
Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial
TRIALS
2015 ;16
-
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
CANCER-AM CANCER SOC
2015 ;121 (15) :2612 -2617
-
Impact of Postoperative Chemoradiotherapy versus Chemotherapy Alone on Recurrence and Survival in Patients with Stage II and III Upper Rectal Cancer: A Propensity Score-Matched Analysis
PLOS ONE
2015 ;10 (4)
-
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
CANCER CHEMOTH PHARM
2015 ;75 (6) :1175 -1182
-
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer
PLOS ONE
2015 ;10 (3)
-
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden
THROMB RES
2015 ;135 (5) :846 -851
-
Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
CLIN CANCER RES
2015 ;21 (11) :2520 -2529
-
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
CANCER RES TREAT
2015 ;47 (4) :687 -696
-
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
CANCER RES TREAT
2015 ;47 (4) :670 -675
-
p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines
CANCER RES TREAT
2015 ;47 (3) :501 -508
-
Effects of Preoperative Chemoradiotherapy on the Likelihood of Sphincter Preservation Surgery in Locally Advanced Distal Rectal Cancer: A Longitudinal Study Based on Pelvic Magnetic Resonance Imaging
ANN SURG ONCOL
2015 ;22 (7) :2159 -2167
-
Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients
CLIN CANCER RES
2015 ;21 (2) :357 -364
-
Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells
ONCOL REP
2015 ;33 (1) :185 -192
-
Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort
CANCER RES TREAT
2015 ;47 (2) :215 -220
-
Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy
SUPPORT CARE CANCER
2015 ;23 (3) :687 -694
-
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
GASTRIC CANCER
2015 ;18 (3) :476 -484
-
Who should be admitted to the intensive care unit? The outcome of intensive care unit admission in stage IIIB-IV lung cancer patients
MED ONCOL
2014 ;31 (3)
-
The early discontinuation of palliative chemotherapy in older patients with cancer
SUPPORT CARE CANCER
2014 ;22 (3) :773 -781
-
Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma
TUMORI
2014 ;100 (4) :439 -445
-
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
BMC CANCER
2014 ;14
-
Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer
THROMB HAEMOSTASIS
2014 ;111 (6) :1112 -1120
-
Prevalence and risk factors for iron deficiency anemia in the korean population: results of the fifth KoreaNational Health and Nutrition Examination Survey
J KOREAN MED SCI
2014 ;29 (2) :224 -229
-
Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis
J CANCER RES CLIN
2014 ;140 (9) :1567 -1574
-
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
CANCER CHEMOTH PHARM
2014 ;74 (3) :447 -455
-
P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer
BMC CANCER
2014 ;14
-
Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy
BREAST CANCER-TOKYO
2014 ;21 (4) :387 -393
-
Gastric cancer with initial bone metastasis: a distinct group of diseases with poor prognosis
EUR J CANCER
2014 ;50 (16) :2810 -2821
-
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
GASTRIC CANCER
2013 ;16 (4) :581 -589
-
Anemia and activities of daily living in the Korean urban elderly population: results from the Korean Longitudinal Study on Health and Aging (KLoSHA)
ANN HEMATOL
2013 ;92 (1) :59 -65
-
Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer
CANCER SCI
2013 ;104 (1) :116 -123
-
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
INVEST NEW DRUG
2013 ;31 (1) :183 -191
-
Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea
JPN J CLIN ONCOL
2013 ;43 (2) :132 -138
-
The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE
THROMB RES
2013 ;131 (4) :e133 -e140
-
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
CANCER CHEMOTH PHARM
2013 ;71 (4) :843 -851
-
A prospective study on the incidence of postoperative venous thromboembolism in Korean gastric cancer patients: an inquiry into the application of Western guidelines to Asian cancer patients
PLOS ONE
2013 ;8 (4)
-
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
INVEST NEW DRUG
2013 ;31 (6) :1547 -1558
-
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
ANN ONCOL
2013 ;24 (11) :2850 -2854
-
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans
ASIAN PAC J CANCER P
2012 ;13 (4) :1209 -1215
-
Toxicities and functional consequences of systemic chemotherapy in elderly Korean patients with cancer: A prospective cohort study using Comprehensive Geriatric Assessment
J GYNECOL ONCOL
2012 ;3 (4) :359 -367
-
Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancers
BMC CANCER
2012 ;12
-
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era
LUNG CANCER
2012 ;76 (3) :387 -392
-
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
INVEST NEW DRUG
2012 ;30 (3) :1164 -1174
-
Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas
CANCER-AM CANCER SOC
2012 ;118 (24) :6162 -6170
-
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
LANCET ONCOL
2012 ;13 (11) :1125 -1132
-
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
LANCET
2012 ;379 (9813) :315 -321
-
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
BMC CANCER
2012 ;12 (1) :1 -10
-
Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy
ANN ONCOL
2012 ;23 (8) :2065 -2071
-
Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer
ANN ONCOL
2012 ;23 (4) :911 -918
-
Efficacy and safety of hepatic arterial infusion of fluorouracil with leucovorin as salvage treatment for refractory liver metastases from colorectal cancer.
Korean J Intern Med
2011 ;26 (1) :82 -88
-
Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population
AM J HEMATOL
2011 ;86 (9) :752 -755
-
The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer.
DIS COLON RECTUM
2011 ;54 (2) :245 -252
-
Comprehensive geriatric assessment in Korean elderly cancer patients receiving chemotherapy
J CANCER RES CLIN
2011 ;137 (5) :839 -847
-
Two consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy.
JPN J CLIN ONCOL
2011 ;41 (3) :430 -433
-
Metastatic Adrenocortical Carcinoma Presenting Simultaneously with Cushing's and Conn's Syndromes: A Case Report
JPN J CLIN ONCOL
2011 ;41 (11) :1287 -1291
-
Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy
GASTRIC CANCER
2011 :1 -9
-
Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients.
THROMB HAEMOSTASIS
2011 ;106 (6) :1084 -1094
-
Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
MED ONCOL
2011 ;28 (4) :991 -998
-
Anaplastic thyroid carcinoma initially presented with abdominal cutaneous mass and hyperthyroidism.
Korean J Intern Med
2010 ;25 (4) :450 -453
-
Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era.
Cancer Res Treat
2010 ;42 (4) :203 -209
-
Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Korean J Intern Med
2010 ;25 (1) :86 -93
-
Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer.
J KOREAN MED SCI
2010 ;25 (5) :684 -90
-
Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less.
BMC CANCER
2010 :557
-
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
CANCER SCI
2010 ;101 (3) :793 -799
-
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer
MED ONCOL
2010 ;27 (3) :992 -997
-
The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer
J THROMB HAEMOST
2010 ;8 :540 -547
-
Prognostic Significance of Pre-operative FDG-PET in Colorectal Cancer
Nucl Med Mol Imaging
2009 ;43 (5) :429 -435
-
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
ANN HEMATOL
2009 ;88 (0) :829 -838
-
Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
JPN J CLIN ONCOL
2009 ;39 (3) :183 -185
-
Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer.
JPN J CLIN ONCOL
2009 ;39 (1) :27 -32
-
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: megnitude of HeR2/neu amplification as a predictive factor for efficacy.
J Korean Med 1
2009
-
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
ANN ONCOL
2009
-
Weight changes after adjuvant treatment in Korean women with early breast cancer.
BREAST CANCER RES
2009
-
Phase Ⅱ study and biomaker analysis of cetuximab combined with codified FOLFOX6 in advanced gastric cancer.
BRIT J CANCER
2009
저서 및 특허 ●
- 2015 The Essentials of Head & Neck Oncology (Oral Cavity Cancer)
- 2011 대장암 예방과 치료 그리고 극복
| 매체명 | 제목 | 발간일 |
|---|---|---|
| 연합뉴스 | "위암 항암제 'S-1' 복용시 눈물길 막힘 부작용 주의" | 2017-08-10 |
| 이데일리 | '타깃단백질분해' 핀테라퓨틱스, 2026 ASCO서 임상 1상 연구 발표
|
2026-05-12 |
| 청년의사 | "항암제 1상, '연구'이면서 '치료'…속도·전략이 신약 운명 결정"
|
2026-04-09 |
| NEWSIS | "건강한 삶 위한 첫걸음"…'암 예방의 날' 맞아 캠페인
|
2026-03-25 |
| 뉴스1 | "14년 만의 표적신약인데"…급여 문턱서 멈춘 위암약 '졸베툭시맙'
|
2026-03-23 |
| 헬스조선 | HER2 양성 위암 치료, 표적치료제 병용요법 가능성 입증
|
2026-03-19 |
| 이데일리 | HER2 양성 위암 치료, 표적치료제 병용요법 가능성 입증
|
2026-03-19 |
| 뉴스1 | HER2 양성위암, 표적치료제 함께 쓰자 종양 크기 81% 감소
|
2026-03-19 |
| NEWSIS | 'HER2' 양성 위암, '이 약물' 병용하니…암 크기 81% 감소
|
2026-03-19 |
| 헤럴드경제 | HER2 양성 위암 치료, 표적치료제 병용요법 가능성 입증
|
2026-03-19 |
| 전자신문 | 분당서울대병원, 엔허투·퍼제타 병용, HER2 양성 위암 종양 억제 효과 ...
|
2026-03-19 |
-
대표전화 : 1588-3369
-
-
Copyright © 분당서울대학교병원. All Rights Reserved.
-
-
KAIT ISO 27001
인증규격 : ISO 27001(정보보호 경영시스템)
유효기간 : 2025.09.26 ~ 2028.09.25 -
KAIT ISO 27701
인증규격 : ISO 27701(개인정보보호 경영시스템)
유효기간 : 2025.09.26 ~ 2028.09.25 -
ISMS 인증
인증범위 : 의료정보시스템(OCS, EMR) 및 홈페이지 서비스 운영
유효기간 : 2024.03.20 ~ 2027.03.19
-
웹접근성 인증
과학기술정보통신부
WEB ACCESSIBILITY -
EMR 7단계 인증
미국외 세계최초
EMR 7단계 인증(2010년) -
보건복지부 의료기관 인증
보건복지부
의료기관 인증 -
BSI ISO 13485
인증규격 : 의료기기 품질경영시스템(디지털의료기기)
유효기간 : 2025.11.13 ~ 2028.11.12 -
GMP
인증규격 : 디지털의료기기 제조 및 품질관리기준
유효기간 : 2026.05.28~2029.05.27
-
KAIT ISO 27001
인증규격 : ISO 27001(정보보호 경영시스템)
